View Filing Data

Document And Entity Information - USD ($) $ in Billions	12 Months Ended
Document And Entity Information - USD ($) $ in Billions	Dec. 31, 2018	Feb. 01, 2019	Jun. 30, 2018
Document Information [Line Items]
Entity Registrant Name	HERON THERAPEUTICS, INC. /DE/
Entity Central Index Key	0000818033
Trading Symbol	hrtx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding (in shares)		78,181,651
Entity Public Float			$ 2.8
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Shell Company	false

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 31,836	$ 144,583
Short-term investments	300,535	27,796
Accounts receivable, net	64,652	41,874
Inventory	39,032	10,108
Prepaid expenses and other current assets	11,193	3,702
Total current assets	447,248	228,063
Property and equipment, net	14,677	5,981
Other assets	254	263
Total assets	462,179	234,307
Current liabilities:
Accounts payable	16,863	18,769
Accrued clinical and manufacturing liabilities	24,470	26,920
Accrued payroll and employee liabilities	13,397	8,860
Other accrued liabilities	32,715	17,175
Deferred revenue		2,763
Promissory note payable to related party		25,000
Convertible notes payable to related parties, net of discount	4,574	3,684
Total current liabilities	92,019	103,171
Commitments and contingencies (see Note 6)
Stockholders’ equity (deficit):
Preferred stock, $0.01 par value: 2,500 shares authorized; no shares issued or outstanding at December 31, 2018 and 2017
Common stock, $0.01 par value: 150,000 shares authorized; 78,174 and 64,609 shares issued and outstanding at December 31, 2018 and 2017, respectively	782	646
Additional paid-in capital	1,330,186	913,955
Accumulated other comprehensive loss	(87)	(10)
Accumulated deficit	(960,721)	(783,455)
Total stockholders’ equity	370,160	131,136
Total liabilities and stockholders’ equity	$ 462,179	$ 234,307

Consolidated Balance Sheets (Parentheticals) - $ / shares shares in Thousands	Dec. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	2,500	2,500
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000	150,000
Common stock, shares issued (in shares)	78,174	64,609
Common stock, shares outstanding (in shares)	78,174	64,609

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Net product sales	$ 77,474	$ 30,767	$ 1,279
Operating expenses:
Cost of product sales	27,512	4,588	35
Research and development	140,032	138,582	103,125
General and administrative	29,263	25,554	21,366
Sales and marketing	64,604	56,601	47,668
Total operating expenses	261,411	225,325	172,194
Loss from operations	(183,937)	(194,558)	(170,915)
Other income (expense), net:
Interest income	5,965	1,049	445
Interest expense	(2,672)	(3,937)	(2,664)
Other (expense) income	1,804	(38)	(9)
Total other income (expense), net	5,097	(2,926)	(2,228)
Net loss	(178,840)	(197,484)	(173,143)
Other comprehensive loss:
Net unrealized gain on short-term investments	(77)	7	23
Comprehensive loss	$ (178,917)	$ (197,477)	$ (173,120)
Basic and diluted net loss per share (in dollars per share)	$ (2.44)	$ (3.65)	$ (4.56)
Shares used in computing basic and diluted net loss per share (in shares)	73,193	54,040	37,925

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2015	36,106,000
Balance at Dec. 31, 2015	$ 361	$ 530,617	$ (40)	$ (412,828)	$ 118,110
Conversion benefit included in Convertible Notes issued		348			348
Issuance of common stock under Employee Stock Purchase Plan (in shares)	55,000
Issuance of common stock under Employee Stock Purchase Plan	$ 1	770			$ 771
Issuance of common stock on exercise of stock options (in shares)	798,000				798,363
Issuance of common stock on exercise of stock options	$ 8	6,676			$ 6,684
Issuance of common stock on exercise of warrants (in shares)	2,396,000
Issuance of common stock on exercise of warrants	$ 24	(24)
Stock-based compensation expense		25,956			25,956
Net loss				(173,143)	(173,143)
Net unrealized gain on short-term investments			23		23
Comprehensive loss					(173,120)
Balance (in shares) at Dec. 31, 2016	39,355,000
Balance at Dec. 31, 2016	$ 394	564,343	(17)	(585,971)	(21,251)
Conversion benefit included in Convertible Notes issued		369			369
Issuance of common stock under Employee Stock Purchase Plan (in shares)	77,000
Issuance of common stock under Employee Stock Purchase Plan	$ 1	988			$ 989
Issuance of common stock on exercise of stock options (in shares)	1,351,000				1,350,605
Issuance of common stock on exercise of stock options	$ 13	11,450			$ 11,463
Issuance of common stock on exercise of warrants (in shares)	4,000
Issuance of common stock on exercise of warrants
Stock-based compensation expense		30,538			30,538
Net loss				(197,484)	(197,484)
Net unrealized gain on short-term investments			7		7
Comprehensive loss					(197,477)
Issuance of common stock in public offerings, net (in shares)	23,822,000
Issuance of common stock in public offerings, net	$ 238	306,041			306,279
Issuance of warrants		226			226
Balance (in shares) at Dec. 31, 2017	64,609,000
Balance at Dec. 31, 2017	$ 646	913,955	(10)	(783,455)	131,136
Conversion benefit included in Convertible Notes issued		392			392
Issuance of common stock under Employee Stock Purchase Plan (in shares)	72,000
Issuance of common stock under Employee Stock Purchase Plan	$ 1	1,178			$ 1,179
Issuance of common stock on exercise of stock options (in shares)	1,530,000				1,529,509
Issuance of common stock on exercise of stock options	$ 15	18,286			$ 18,301
Stock-based compensation expense		33,367			33,367
Net loss				(178,840)	(178,840)
Net unrealized gain on short-term investments			(77)		(77)
Comprehensive loss					(178,917)
Issuance of common stock in public offerings, net (in shares)	11,963,000
Issuance of common stock in public offerings, net	$ 120	363,008			363,128
Balance (in shares) at Dec. 31, 2018	78,174,000
Balance at Dec. 31, 2018	$ 782	1,330,186	(87)	(960,721)	370,160
Cumulative Effect of New Accounting Principle in Period of Adoption				$ 1,574	$ 1,574

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating activities:
Net loss	$ (178,840)	$ (197,484)	$ (173,143)
Adjustments to reconcile net loss to net cash used for operating activities:
Stock-based compensation expense	33,367	30,538	25,956
Depreciation and amortization	1,513	1,531	1,099
Amortization of debt discount	890	773	689
(Accretion of discount) amortization of premium on short-term investments	(3,412)	(278)	274
Impairment of property and equipment	72
Loss on disposal of property and equipment	29	39	9
Change in operating assets and liabilities:
Accounts receivable	(22,778)	(39,914)	(1,960)
Prepaid expenses and other assets	(7,482)	3	(338)
Inventory	(29,122)	(4,768)	(5,340)
Accounts payable	(1,906)	11,955	3,514
Accrued clinical and manufacturing liabilities	(3,614)	13,713	7,976
Accrued payroll and employee liabilities	4,537	446	3,586
Deferred revenue		1,664	1,099
Other accrued liabilities	14,941	11,482	2,482
Net cash used for operating activities	(191,805)	(170,300)	(134,097)
Investing activities:
Purchases of short-term investments	(497,104)	(121,570)	(43,318)
Maturities of short-term investments	227,700	131,783	61,329
Purchases of property and equipment	(9,171)	(2,553)	(3,135)
Proceeds from the sale of property and equipment	25	78
Net cash (used for) provided by investing activities	(278,550)	7,738	14,876
Financing activities:
Net proceeds from sale of common stock and/or pre-funded warrants	363,128	306,279
Proceeds from purchases under the Employee Stock Purchase Plan	1,179	989	771
Proceeds from stock option exercises	18,301	11,463	6,684
Proceeds from issuance of promissory note payable to related party			50,000
Repayment of promissory note payable to related party	(25,000)	(25,000)
Net cash provided by financing activities	357,608	293,731	57,455
Net (decrease) increase in cash and cash equivalents	(112,747)	131,169	(61,766)
Cash and cash equivalents at beginning of year	144,583	13,414	75,180
Cash and cash equivalents at end of year	31,836	144,583	13,414
Supplemental disclosure of cash flow information:
Interest paid	1,183	2,789	1,622
Cumulative effect of adoption of new accounting standard	$ 1,574

Note 1 - Organization and Business	12 Months Ended
Note 1 - Organization and Business	Dec. 31, 2018
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Organization and Business Heron Therapeutics, Inc. (“Company”, “Heron”, or “we”) is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, our first commercial product, SUSTOL, was approved by the U.S. Food and Drug Administration (“FDA”). SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is an extended-release, injectable 5 -hydroxytryptamine type 3 ( “5 - HT3” ) receptor antagonist that utilizes Heron’s Biochronomer Technology to maintain therapeutic levels of granisetron for ≥5 days. We commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017, our second commercial product, CINVANTI, was approved by the FDA. CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). CINVANTI is an intravenous (“IV”) formulation of aprepitant, a substance P/neurokinin- 1 ( “NK1” ) receptor antagonist. CINVANTI is the only IV formulation of an NK1 receptor antagonist indicated for the prevention of acute and delayed nausea and vomiting associated with HEC and nausea and vomiting associated with MEC that is free of polysorbate 80 or any other synthetic surfactant. We commenced commercial sales of CINVANTI in the U.S. in January 2018. HTX- 011, which utilizes Heron’s proprietary Biochronomer Technology, is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for postoperative pain management. By delivering sustained levels of both a potent anesthetic and a local anti-inflammatory agent directly to the site of tissue injury, HTX- 011 was designed to deliver superior pain relief while reducing the need for systemically administered pain medications such as opioids, which carry the risk of harmful side effects, abuse and addiction. HTX- 011 has been shown to reduce pain significantly better than placebo or bupivacaine alone in five diverse surgical models: hernia repair, abdominoplasty, bunionectomy, total knee arthroplasty and breast augmentation. HTX- 011 was granted Fast Track designation from the FDA in the fourth quarter of 2017 and Breakthrough Therapy designation in the second quarter of 2018. The FDA recently accepted our New Drug Application NDA for HTX- 011, and has granted it a Priority Review designation. The FDA set a Prescription Drug User Fee Act goal date of April 30, 2019 and indicated that it is not currently planning an advisory committee meeting to discuss this application. HTX- 034, our next-generation product candidate for postoperative pain management, is in development for postoperative pain via local application. Based on the positive results of preclinical studies in which HTX- 034 demonstrated significant pain reduction for seven days, we have initiated formal development of this next-generation postoperative pain management product candidate. As of December 31, 2018, we had $332.4 million in cash, cash equivalents and short-term investments. We have incurred significant operating losses and negative cash flows from operations. Management believes that cash, cash equivalents and short-term investments as of December 31, 2018 will be sufficient to fund operations for at least one year from the date this Annual Report on Form 10 -K is filed with the U.S. Securities and Exchange Commission (“SEC”).

Note 2 - Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Significant Accounting Policies [Text Block]

2.	Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Heron Therapeutics, Inc. and its wholly owned subsidiary, Heron Therapeutics, B.V., which was organized in the Netherlands in

March 2015.

Heron Therapeutics, B.V. has

operations and

material assets or liabilities, and there have been

significant transactions related to Heron Therapeutics, B.V. since its inception.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our significant accounting policies that involve significant judgment and estimates include revenue recognition, inventory and related reserves, accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates.

Cash,

Cash Equivalents

and Short-Term Investments

Cash and cash equivalents consist of cash and highly liquid investments with contractual maturities of

three

months or less from the original purchase date.

Short-term investments consist of securities with contractual maturities of greater than

three

months to

one

year from the original purchase date. We have classified our short-term investments as available-for-sale securities in the accompanying consolidated financial statements. Available-for-sale securities are stated at fair market value, with the net change in unrealized gains and losses reported in other comprehensive loss and realized gains and losses included in other income (expense), net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.

Our bank and investment accounts have been placed under control agreements in accordance with our Senior Secured Convertible Notes (“Convertible Notes”) (see Note

Fair Value of Financial Instruments

A company

may

elect to use fair value to measure accounts and loans receivable, available-for-sale and held-to-maturity securities, equity method investments, accounts payable, guarantees and issued debt. Other eligible items include firm commitments for financial instruments that otherwise would

not

be recognized at inception and non-cash warranty obligations where a warrantor is permitted to pay a

third

party to provide the warranty goods or services. If the use of fair value is elected, any upfront costs and fees related to the item such as debt issuance costs must be recognized in earnings and cannot be deferred. The fair value election is irrevocable and generally made on an instrument-by-instrument basis, even if a company has similar instruments that it elects

not

to measure based on fair value. Unrealized gains and losses on existing items for which fair value has been elected are reported as a cumulative adjustment to beginning retained earnings and any changes in fair value are recognized in earnings. We have elected to

not

apply the fair value option to our financial assets and liabilities.

Financial instruments, including cash and cash equivalents, receivables, inventory, prepaid expenses, other current assets, accounts payable and accrued expenses, are carried at cost, which is considered to be representative of their respective fair values because of the short-term maturity of these instruments. Short-term available-for-sale investments are carried at fair value (see Note

). Our Convertible Notes outstanding at

December

31,

2018

not

have a readily available ascertainable market value, however, the carrying value is considered to approximate its fair value.

Concentration of Credit Risk

Cash, cash equivalents and short-term investments are financial instruments that potentially subject us to concentrations of credit risk. We deposit our cash in financial institutions. At times, such deposits

may

be in excess of insured limits. We

may

also invest our excess cash in money market funds, U.S. government and agencies, corporate debt securities and commercial paper. We have established guidelines relative to our diversification of our cash investments and their maturities in an effort to maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.

Our products are distributed in the U.S. through a limited number of specialty distributors and full line wholesalers (collectively, “Customers”) that resell our products to healthcare providers and hospitals, the end users.

The following table includes the percentage of net product sales and accounts receivable balances for our

three

major Customers, each of which comprised

10%

or more of our net product sales:

	Net Product Sales			Accounts Receivable
	Year Ended December 31 , 2018			As of December 31 , 2018

Customer A		41.7	%		38.7	%
Customer B		34.9	%		46.1	%
Customer C		22.5	%		14.8	%
Total		99.1	%		99.6	%

Accounts Receivable, Net

Accounts receivable are recorded at the invoice amount, net of an allowance for doubtful accounts. The allowance for doubtful accounts reflects accounts receivable balances that are believed to be uncollectible. In estimating the allowance for doubtful accounts, we consider: (

) our historical experience with collections and write-offs; (

) the credit quality of our Customers and any recent or anticipated changes thereto; and (

) the outstanding balances and past due amounts from our Customers.

We offered extended payment terms to our Customers in connection with our product launches of SUSTOL and CINVANTI in

October 2016

and

January 2018,

respectively, in anticipation of the timing in reimbursement by government and commercial payers. Effective

January 2018,

we shortened payment terms to certain of our SUSTOL Customers. As of

December 31, 2018,

extended payment terms given to our Customers were evaluated in accordance with GAAP and did

not

impact the collectability of accounts receivables.

As of

December 31, 2018,

we determined that an allowance for doubtful accounts was

not

required. For the year ended

December 31, 2018,

we did

not

write off any accounts receivable balances.

Inventory

Inventory is stated at the lower of cost or estimated net realizable value on a

first

-in,

first

-out, or FIFO, basis. We periodically analyze our inventory levels and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and inventory quantities that are in excess of expected sales requirements as cost of product sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory

may

be required, which would be recorded as cost of product sales.

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets (generally

five

years). Leasehold improvements are stated at cost and amortized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term.

Impairment of Long-Lived Assets

If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and record the impairment as a reduction in the carrying value of the related asset with a corresponding charge to operating expenses. Estimating the undiscounted future operating cash flows associated with long-lived assets requires judgment and assumptions that could differ materially from actual results.

Revenue Recognition

May 2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

No.

2014

09,

Revenue from Contracts with Customers

(“Topic

606”

). Topic

606

is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Topic

606

is effective for fiscal years beginning after

December 15, 2017,

including interim periods within those fiscal years. Accordingly, in the

first

quarter of

2018,

we adopted Topic

606

using the modified retrospective approach. Under this approach, incremental disclosures are provided to present each financial statement line item for

2018

under the prior standard. As a result of the adoption of Topic

606,

we recorded a cumulative adjustment to accumulated deficit of

$1.6

million on

January 1, 2018.

This adjustment reflects the acceleration of

$2.9

million in gross product sales less

$1.1

million in product sales allowances and

$0.2

million in cost of product sales (see Note

Accrued Clinical Liabilities

We accrue clinical costs based on work performed, which relies on estimates of the progress of the trials and the related expenses incurred. Clinical trial related contracts vary significantly in duration, and

may

be for a fixed amount, based on the achievement of certain contingent events or deliverables, a variable amount based on actual costs incurred, capped at a certain limit or contain a combination of these elements. Revisions are recorded to research and development expense in the period in which the facts that give rise to the revision become known. Historically, revisions have

not

resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a clinical trial could result in a material charge to our results of operations.

Research and Development Expense

All costs of research and development are expensed in the period incurred. Research and development expense primarily consist of personnel and related costs, stock-based compensation expense, fees paid to outside service providers and consultants, facilities costs and materials used in clinical and preclinical trials and research and development.

Patent Costs

We incur outside legal fees in connection with filing and maintaining our various patent applications. All patent costs are expensed as incurred and are included in general and administrative expense in the consolidated statements of operations and comprehensive loss.

Stock-Based Compensation Expense

We estimate the fair value of stock-based payment awards using the Black-Scholes option pricing model. This fair value is then amortized using the straight-line single-option method of attributing the value of stock-based compensation to expense over the requisite service periods of the awards. The Black-Scholes option pricing model requires the input of complex and subjective assumptions, including each option’s expected life and price volatility of the underlying stock.

As stock-based compensation expense is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based on historical data.

Warrants

We have issued warrants to purchase shares of our common stock in conjunction with certain equity financings or in exchange for services. The terms of the warrants were evaluated to determine the appropriate classification as equity or a liability.

Income Taxes

We recognize the impact of a tax position in our consolidated financial statements if the position is more likely than

not

to be sustained on examination and on the technical merits of the position. The total amount of unrecognized tax benefits, if recognized, would affect other tax accounts, primarily deferred taxes in future periods, and would

not

affect our effective tax rate, since we maintain a full valuation allowance against our deferred tax assets (see Note

). We recognize interest and penalties related to income tax matters in income tax expense.

Comprehensive

Loss

Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net changes in unrealized gains and losses on available-for-sale securities are included in other comprehensive loss and represent the difference between our net loss and comprehensive net loss for all periods presented.

Net Loss

per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common share equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and shares of common stock underlying Convertible Notes are considered to be common stock equivalents and are included in the calculation of diluted net loss per share only when their effect is dilutive.

Because we have incurred a net loss for all periods presented in the consolidated statements of operations and comprehensive loss, the following common stock equivalents were

not

included in the computation of net loss per share because their effect would be anti-dilutive (in thousands):

	December 31 ,
	2018		2017		2016

Stock options outstanding		15,265		13,463		11,845
Warrants outstanding		640		620		600
Shares of common stock underlying Convertible Notes outstanding		8,473		7,983		7,521

Recent Accounting Pronouncements

Recently Adopted

May 2017,

the FASB issued ASU

No.

2017

09,

Compensation – Stock Compensation: Scope of Modification Accounting

(“ASU

2017

09”

The amendments in ASU

2017

provide guidance about which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting in Topic

718.

In the

first

quarter of

2018,

we adopted the provisions of ASU

2017

09,

which did

not

have a material impact on our results of operations or financial condition.

Not

Yet Adopted

February 2016,

the FASB issued ASU

No.

2016

02,

Leases (Topic

842

)

(“ASU

2016

02”

which provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. In

July 2018,

the FASB issued ASU

No.

2018

11,

Leases (Topic

842

): Targeted Improvements

and ASU

No.

2018

10,

Codification Improvements to Topic

842,

Leases

. ASU

2016

and the subsequent modifications are identified as “ASC

842.”

ASC

842

requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or

not

the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than

twelve

months, regardless of classification. Leases with a term of

twelve

months or less will be accounted for similar to existing guidance for operating leases. ASC

842

is effective for fiscal years beginning after

December 15, 2018,

including interim periods within those fiscal years. We adopted the provisions of ASU

2016

January 1, 2019

using the alternative modified transition method. We are still in the process of finalizing our assessment of the impact of ASC

842

on our results of operations and related disclosures. We are also implementing additional internal controls to enable future preparation of financial information and disclosures in accordance with ASC

842.

August 2018,

the FASB issued ASU

No.

2018

13,

Fair Value Measurement (Topic

820

) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement

(“ASU

2018

13”

), which is designed to improve the effectiveness of disclosures by removing, modifying and adding disclosures related to fair value measurements. ASU

2018

is effective for fiscal years beginning after

December 15, 2019,

including interim periods within those fiscal years. Early adoption is permitted. We plan to adopt the provisions of ASU

2018

in the

first

quarter of

2020,

and we are currently evaluating the impact on our consolidated financial statements.

Note 3 - Fair Value Measurements

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Fair Value Disclosures [Text Block]

3.	Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The FASB Accounting Standards Codification (“ASC”) Topic

820,

Fair Value Measurements & Disclosures

, establishes a fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:

•

Level

— Observable inputs such as quoted prices in active markets for identical assets or liabilities.

•

Level

— Inputs other than Level

that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are

not

active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level

— Unobservable inputs that are supported by little or

market activity and that are significant to the fair value of the assets or liabilities.

We measure cash equivalents and short-term investments at fair value on a recurring basis. The fair values of these such assets were as follows (in thousands):

			Fair Value Measurements at Reporting Date Using
			Quoted Prices in		Significant
			Active Markets		Other		Significant
	Balance at		for Identical		Observable		Unobservable
	December 31,		Assets		Inputs		Inputs
	2018		(Level 1)		(Level 2)		(Level 3)
Money market funds	$	13,874	$	13,874	$	—	$	—
U.S. treasury bills and government agency obligations		59,741		59,741		—		—
U.S. corporate debt securities		59,087		—		59,087		—
Foreign corporate debt securities		5,046		—		5,046		—
U.S. commercial paper		61,885		—		61,885		—
Foreign commercial paper		123,861		—		123,861		—
Total	$	323,494	$	73,615	$	249,879	$	—

			Fair Value Measurements at Reporting Date Using
			Quoted Prices in		Significant
			Active Markets		Other		Significant
	Balance at		for Identical		Observable		Unobservable
	December 31 ,		Assets		Inputs		Inputs
	2017		(Level 1)		(Level 2)		(Level 3)
Money market funds	$	91,386	$	91,386	$	—	$	—
U.S. corporate debt securities		17,520		—		17,520		—
U.S. commercial paper		39,863		—		39,863		—
Foreign commercial paper		19,854		—		19,854		—
Total	$	168,623	$	91,386	$	77,237	$	—

We have

not

transferred any investment securities between the

three

levels of the fair value hierarchy.

As of

December 31, 2018,

cash equivalents included

$9.1

million of available-for-sale securities with contractual maturities of

three

months or less, and short-term investments included

$300.5

million of available-for-sale securities with contractual maturities of

three

months to

one

year. As of

December 31, 2017,

cash equivalents included

$49.4

million of available-for-sale securities with contractual maturities of

three

months or less, and short-term investments included

$27.8

million of available-for-sale securities with contractual maturities of

three

months to

one

year. The money market funds as of

December 31, 2018

and

2017

are included in cash and cash equivalents on the consolidated balance sheets.

Unrealized gains and losses associated with our investments are reported in accumulated other comprehensive loss. For the year ended

December 31, 2018,

we recorded

$77,000

in net unrealized losses associated with our short-term investments. For the years ended

December 31, 2017

and

2016,

we recorded

$7,000

and

$23,000,

respectively, in net unrealized gains associated with our short-term investments.

Realized gains and losses associated with our investments, if any, are reported in the statements of operations and comprehensive loss. We did

not

recognize any realized gains or losses during the years ended

December 31, 2018,

2017

and

2016.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 4 - Balance Sheet Details

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Supplemental Balance Sheet Disclosures [Text Block]

4.	Balance Sheet Details

Short-Term

Investments

The following is a summary of our short-term investments (in thousands):

	December 31, 201 8
			Gross		Gross
	Amortized		Unrealized		Unrealized			Estimated
	Cost		Gains		Losses			Fair Value
U.S. treasury bills and government agency obligations	$	59,747	$	—	$	(6	)	$	59,741
U.S. corporate debt		59,164		—		(77	)		59,087
Foreign corporate debt		5,041		5		—			5,046
U.S. commercial paper		52,800		—		—			52,800
Foreign commercial paper		123,870		—		(9	)		123,861
Total	$	300,622	$	5	$	(92	)	$	300,535

	December 31, 201 7
			Gross		Gross
	Amortized		Unrealized		Unrealized			Estimated
	Cost		Gains		Losses			Fair Value
U.S. corporate debt securities	$	13,003	$	—	$	(10	)	$	12,993
U.S. commercial paper		4,929		—		—			4,929
Foreign commercial paper		9,874		—		—			9,874
Total	$	27,806	$	—	$	(10	)	$	27,796

The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. We regularly monitor and evaluate the realizable value of our marketable securities. We did

not

recognize any impairment losses for the years ended

December 31, 2018

and

2017.

Inventory

Inventory consists of the following (in thousands):

	December 31,
	2018		2017
Raw materials	$	10,112	$	2,754
Work in process		20,604		4,166
Finished goods		8,316		3,188
Total inventory	$	39,032	$	10,108

As of

December 31, 2018,

total inventory included

$6.7

million related to SUSTOL and

$32.3

million related to CINVANTI. As of

December 31, 2017,

total inventory included

$7.1

million related to SUSTOL and

$3.0

million related to CINVANTI.

Property and Equipment

Property and equipment, net consists of the following (in thousands):

	December 31,
	2018			2017
Scientific equipment	$	18,077		$	9,742
Leasehold improvements		1,783			1,654
Computer equipment and software		1,190			1,420
Furniture, fixtures and office equipment		1,722			1,024
Property and equipment, gross		22,772			13,840
Less: accumulated depreciation and amortization		(8,095	)		(7,859	)
Property and equipment, net	$	14,677		$	5,981

Depreciation and amortization expense for the years ended

December

31,

2018,

2017

and

2016

was

$1.5

million,

$1.5

million and

$1.1

million, respectively. As of

December 31, 2018

and

2017,

$10.3

million and

$2.0

million of property and equipment, respectively, was in process and

not

depreciated during the respective years.

Accrued Payroll and Employee Liabilities and Other Accrued

Liabilities

Accrued payroll and employee liabilities consist of the following (in thousands):

	December 31,
	20 18		2017
Accrued employee salaries and benefits	$	2,330	$	1,292
Accrued bonuses		9,139		5,044
Accrued vacation		1,928		1,438
Accrued expenses for realignment (see Note 7)		—		1,086
Total accrued payroll and employee liabilities	$	13,397	$	8,860

Other accrued liabilities consist of the following (in thousands):

	December 31,
	2018		2017
Accrued product sales allowances	$	25,503	$	9,319
Accrued consulting and professional fees		5,768		6,869
Deferred rent		780		651
Accrued accounts payable		224		148
Other accrued liabilities		440		188
Total other accrued liabilities	$	32,715	$	17,175

Note 5 - Revenue Recognition

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

Revenue Recognition

Product Sales

SUSTOL is distributed in the U.S. through a limited number of Customers that resell SUSTOL to healthcare providers, the end users of SUSTOL. CINVANTI is distributed in the U.S. through a limited number of Customers that resell CINVANTI to healthcare providers and hospitals, the end users of CINVANTI.

Adoption of Topic

606

January 1, 2018,

we adopted Topic

606

using the modified retrospective approach applied to those contracts that were

not

completed as of

January 1, 2018.

Results from reporting periods beginning after

January 1, 2018

are presented under Topic

606,

while prior period amounts are

not

adjusted and continue to be reported in accordance with our historical accounting under the FASB ASC Topic

605,

Revenue Recognition

(“Topic

605”

). Prior to the adoption of Topic

606,

we recognized product sales as revenue to the extent that our Customers had resold our products to end users (sell-through approach). With the adoption of Topic

606,

we recognize product sales as revenue when our products are sold to our Customers (sell-in approach). Product sales under both Topic

605

and

606

are reported net of product sales allowances, which include product returns.

Revenue is recognized in an amount that reflects the consideration we expect to receive in exchange for our products. To determine revenue recognition for contracts with customers within the scope of Topic

606,

we performed the following

five

steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations of the contract(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract(s); and (v) recognize revenue when (or as) we satisfy the performance obligations.

The following table shows the reconciliation of assets and liabilities disclosed in our Annual Report on Form

-K for the year ended

December 31, 2017,

as adjusted, due to the modified retrospective adoption of Topic

606

January 1, 2018 (

in thousands):

	As Reported Under Topic 605			Effect of Change			As Adjusted Under Topic 606

Inventory	$	10,108		$	(198	)	$	9,910
Other accrued liabilities		17,175			991			18,166
Deferred revenue		2,763			(2,763	)		—
Accumulated deficit		(783,455	)		1,574			(781,881	)

The following table shows the unaudited condensed consolidated financial statement line items as if revenue from contracts with customers had been accounted for under Topic

605

(in thousands, except per share data):

	As Reported Under Topic 606			Effect of Change			As Calculated Under Topic 605

Consolidated Balance Sheet as of December 31, 2018:
Inventory	$	39,032		$	2,181		$	41,213
Other accrued liabilities		32,715			(7,195	)		25,520
Deferred revenue		—			14,010			14,010
Accumulated deficit		(960,721	)		(4,634	)		(965,355	)

Consolidated Statement of Operations for the Year Ended December 31 , 2018 :
Net product sales	$	77,474		$	(5,043	)	$	72,431
Cost of product sales		27,512			(1,983	)		25,529
Loss from operations		(183,937	)		(3,060	)		(186,997	)
Net loss		(178,840	)		(3,060	)		(181,900	)
Basic and diluted net loss per share		(2.44	)		(0.05	)		(2.49	)

Consolidated Statement of Cash Flows for the Year Ended December 31 , 2018 :
Net loss	$	(178,840	)	$	(3,060	)	$	(181,900	)
Adjustments to reconcile net loss to net cash used in operating activities:
Inventory		(29,122	)		(1,983	)		(31,105	)
Other accrued liabilities		14,941			(6,204	)		8,737
Deferred revenue		—			11,247			11,247

Product Sales Allowances

We recognize product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with Customers, historical product returns, rebates or discounts taken, the shelf life of the product and specific known market events, such as competitive pricing and new product introductions. If actual future results vary from our estimates, we

may

need to adjust these estimates, which could have an effect on product sales and earnings in the period of adjustment. Our product sales allowances include:

●

Product Returns — We allow our Customers to return product for credit

months after its product expiration date. As such, there

may

be a significant period of time between the time the product is shipped and the time the credit is issued on returned product.

●

Distributor Fees — We offer contractually determined discounts to our Customers. These discounts are paid

later than

two

months after the quarter in which product was shipped.

●

Group Purchasing Organization (“GPO”) Discounts and Rebates — We offer cash discounts to GPO members. These discounts are taken when the GPO members purchase SUSTOL or CINVANTI from our Customers, who then charge back to us the discount amount. Additionally, we offer volume and contract-tier rebates to GPO members. Rebates are based on actual purchase levels during the quarterly rebate purchase period.

●

GPO Administrative Fees — We pay administrative fees to GPOs for services and access to data. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the GPOs’ members.

●

Medicaid Rebates — We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within

three

months after the quarter in which SUSTOL or CINVANTI was sold.

We believe our estimated allowance for product returns requires a high degree of judgment and is subject to change based on our experience and certain quantitative and qualitative factors. We believe our estimated allowances for distributor fees, GPO discounts, rebates and administrative fees and Medicaid rebates do

not

require a high degree of judgment because the amounts are settled within a relatively short period of time.

Our product sales allowances and related accruals are evaluated each reporting period and adjusted when trends or significant events indicate that a change in estimate is appropriate. Changes in sales allowance estimates could materially affect our results of operations and financial position.

The following table provides a summary of activity with respect to our product returns, distributor fees and discounts, rebates and administrative fees, which are included in other accrued liabilities on the condensed consolidated balance sheets (in thousands):

	Product Returns			Distributor Fees			Discounts, Rebates and Administrative Fees			Total

Balance at December 31, 2017	$	521		$	580		$	8,218		$	9,319
Provision		464			7,555			58,504			66,523
Payments/credits		(38	)		(5,322	)		(44,979	)		(50,339	)
Balance at December 31, 2018	$	947		$	2,813		$	21,743		$	25,503

Note 6 - Commitments and Contingencies

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

6 .	Commitments and Contingencies

Leases

We lease

28,275

square feet of laboratory and office space in San Diego, California under a lease that began on

December 1, 2016

and expires on

April 15, 2024.

May 2018,

we entered into a lease amendment to expand our space in San Diego, adding an additional

23,873

square feet. The lease of the additional space began on

September 7, 2018

and expires on

December 31, 2025.

We have

one

-year option to renew this lease on expiration. We lease

26,067

square feet of laboratory, office and warehouse space in Redwood City, California. The lease for the Redwood City space expires on

May 31, 2019.

March 15, 2018,

we entered into a sublease agreement for the Redwood City property. The sublease agreement expires on

May 31, 2019.

We also lease

1,898

square feet of office space in Jersey City, New Jersey. The lease for the Jersey City office space expires on

June 30, 2019.

For the year ended

December 31, 2018,

rent expense for all properties was

$3.2

million. We believe our facilities are adequate and suitable for our current needs and that we will be able to obtain new or additional leased space in the future when necessary.

Annual future minimum lease payments as of

December

31,

2018

are as follows (in thousands):

Year ended December 31:
2019	$	3,195
2020		2,722
2021		2,801
2022		2,883
2023		2,967
Thereafter		3,274
Total future minimum lease payments	$	17,842

Rent expense under all operating leases totaled

$3.2

million,

$3.1

million and

$2.1

million for the years ended

December

31,

2018,

2017

and

2016,

respectively.

Clinical Development Agreements

We enter into agreements with clinical sites and clinical research organizations for the conduct of our clinical trials. We make payments to these sites and organizations based in part on the number of eligible patients enrolled and the length of their participation in the clinical trials. Under certain of these agreements, we

may

be subject to penalties in the event that we prematurely terminate these agreements. At this time, due to the variability associated with clinical site and contract research organization agreements, we are unable to estimate with certainty the future costs we will incur. We intend to use our current financial resources to fund our obligations under these commitments.

Note 7 - Realignment of Goals and Objectives and New Development Focus	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	7. Realignment of Goals and Objectives and New Development Focus Following the approval of SUSTOL and consistent with our transition into a commercial-stage biotechnology company, we realigned our goals and objectives and refocused our development efforts to the area of postoperative pain management. On September 30, 2016, the Board of Directors accepted the resignations of three executive officers, and these executive officers and other employees directly affected by the realignment and refocusing were or will be provided with one -time severance payments on termination, continued benefits for a specified period of time and outplacement assistance. The total expense for these activities was $9.4 million, $5.5 million of which is primarily for severance and $3.9 million of which is for non-cash, stock-based compensation expense. The total expense was recognized between September 30, 2016 and December 31, 2017. As of December 31, 2018, we have paid all of the cash severance charges. In March 2018, we shut down operations at our Redwood City facility and entered into a sublease agreement for the remainder of the lease term. The fair value of the cease-use liability was calculated using the remaining lease payments, offset by future sub-lease payments, deferred rent amortization and prepaid rent amounts. In the first quarter of 2018, we recorded expense of $0.5 million to general and administrative expense as a loss on the lease. We have accounted for these expenses in accordance with ASC Topic 420, Exit or Disposal Cost Obligations .

Note 8 - Secured Notes to Related Party	12 Months Ended
Note 8 - Secured Notes to Related Party	Dec. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	8 . Secured Notes to Related Party Convertible Notes In April 2011, we entered into a securities purchase agreement for a private placement of up to $4.5 million in Convertible Notes with certain investors, including Tang Capital Partners, LP (“TCP”). TCP is controlled by Tang Capital Management, LLC (“TCM”). The manager of TCM is Kevin C. Tang, who served as a director at the time and currently serves as the Chairman of our Board of Directors. At the time of issuance, the terms of the Convertible Notes were determined by our independent directors to be no less favorable than terms that would be obtained in an arm’s length financing transaction. We received a total of $4.3 million, net of issuance costs, from the issuance of these Convertible Notes. The Convertible Notes are secured by substantially all of our assets, including placing our bank and investment accounts under a control agreement. The Convertible Notes bear interest at 6% per annum, payable quarterly in cash or in additional principal amount of Convertible Notes, at the election of the purchasers. The Convertible Notes mature on May 2, 2021; however, the holders of the Convertible Notes may require prepayment of the Convertible Notes at any time, at each holder’s option. The Convertible Notes are convertible into shares of our common stock at a rate of 1,250 shares for every $1,000 of outstanding principal due under the Convertible Notes. There is no right to convert the Convertible Notes to the extent that, after giving effect to such conversion, the holder would beneficially own in excess of 9.99% of our outstanding common stock. Each holder of the Convertible Notes can increase or decrease this beneficial ownership conversion limit by written notice to us, which will not be effective until 61 days after delivery of the notice. As of December 31, 2018, we were in compliance with all covenants under the Convertible Notes. On the occurrence of an event of default under the Convertible Notes, the holders of the Convertible Notes have the right to require us to redeem all or a portion of their Convertible Notes. In 2011, we filed a registration statement with the SEC to register for resale 3.5 million shares underlying the Convertible Notes. The registration statement was declared effective on July 29, 2011. The Convertible Note holders have agreed to waive their right to require us to maintain the effectiveness of the registration statement and to register the additional shares underlying the Convertible Notes until they provide notice otherwise. The Convertible Notes contain an embedded conversion feature that was in-the-money on the issuance dates. Based on an effective fixed conversion rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Convertible Notes, the total conversion benefit at issuance exceeded the loan proceeds. Therefore, a debt discount was recorded in an amount equal to the face value of the Convertible Notes on the issuance dates, and we began amortizing the resultant debt discount over the respective 10 -year term of the Convertible Notes. During the year ended December 31, 2018, accrued interest of $0.4 million was paid-in-kind and rolled into the Convertible Note principal balance, which resulted in an additional debt discount of $0.4 million. For the years ended December 31, 2018, 2017 and 2016, interest expense relating to the stated rate was $0.4 million for each of the three periods. Interest expense relating to the amortization of the debt discount was $0.9 million, $0.8 million and $0.7 million, respectively. As of December 31, 2018, the carrying value of the Convertible Notes was $4.6 million, which is comprised of the $6.8 million principal amount of the Convertible Notes outstanding, less debt discount of $2.2 million. As of December 31, 2018, the Convertible Notes were convertible into 8.5 million shares of our common stock. Promissory Note In August 2016, we entered into the Subordinated Secured Promissory Note (“Promissory Note”) with TCP whereby TCP agreed to lend us up to $100.0 million. The Promissory Note had a two -year term and bore interest at a rate of 8% per annum. The first close of $50.0 million occurred on August 5, 2016. The second close of an additional $50.0 million was not drawn and expired prior to the draw down. There were no fees, no warrants and no equity conversion features associated with this transaction. The Promissory Note was secured by a second -priority lien on substantially all of our assets. TCP is controlled by TCM. The manager of TCM is Kevin C. Tang, who serves as the Chairman of our Board of Directors. The terms of the Promissory Note were determined by our independent directors to be no less favorable than terms that would be obtained in an arm’s length financing transaction. For the year ended December 31, 2018, interest expense was $1.2 million, compared to $2.8 million for the same period in 2017. In August 2018, we paid the remaining obligation under the Promissory Note, which included $25.0 million of outstanding principal and $0.2 million of accrued interest. As of December 31, 2018, there were no remaining obligations under the Promissory Note.

Note 9 - Stockholders' Equity

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

Stockholders’ Equity

2017

Common Stock Offering

January 2017,

we sold

14.1

million shares of our common stock at a public offering price of

$12.20

per share. We received total net proceeds of

$163.7

million (net of

$8.8

million in issuance costs) from the sale of the common stock.

December 2017,

we sold

9.7

million shares of our common stock at a public offering price of

$15.50

per share. We received total net proceeds of

$142.6

million (net of

$7.4

million in issuance costs) from the sale of the common stock.

2018

Common Stock Offerings

April 2018,

we sold

6.9

million shares of our common stock at a public offering price of

$26.00

per share. We received total net cash proceeds of

$168.7

million (net of

$10.7

million in issuance costs) from the sale of the common stock.

June 2018,

we sold

5.1

million shares of our common stock at a public offering price of

$39.50

per share. We received total net cash proceeds of

$194.4

million (net of

$5.6

million in issuance costs) from the sale of the common stock.

Public Offering Warrants

June 2014,

as a component of our public offering, we sold

600,000

pre-funded warrants to purchase shares of our common stock. The pre-funded warrants have an exercise price of

$0.01

per share and expire on

June 30, 2021.

During the year ended

December 31, 2017,

warrant holders exercised

4,426

warrants under the cashless exercise provision in each such holder’s warrant, which resulted in the net issuance of

4,423

shares of common stock and

net cash proceeds to us. As of

December 31, 2018,

595,574

warrants from the

June 2014

public offering remain outstanding.

Common Stock Reserved for Future Issuance

Shares of our common stock reserved for future issuance as of

December

31,

2018

were as follows:

	Number of Shares
Stock options outstanding		15,264,606
Stock options available for grant		1,354,280
Employee stock purchase plan		195,818
Warrants outstanding		640,164
Shares of common stock underlying Convertible Notes outstanding (see Note 8)		8,472,820
Total shares reserved for future issuance		25,927,688

Employee Stock Purchase Plan

1997,

our stockholders approved our Employee Stock Purchase Plan (“ESPP”). In

December 2007,

May 2009,

June 2011,

May 2014,

May 2015,

June 2016

and

June 2017,

our stockholders authorized increases in the number of shares reserved for issuance under the ESPP by

5,000,

10,000,

25,000,

100,000,

100,000

and

200,000

shares, respectively, for a total of

475,000

shares reserved at

December 31, 2018.

Under the terms of the ESPP, employees can elect to have up to a maximum of

10%

of their base earnings withheld to purchase our common stock. The purchase price of the stock is

85%

of the lower of the closing prices for our common stock on: (i) the

first

trading day in the enrollment period, as defined in the ESPP, in which the purchase is made, or (ii) the purchase date. The length of the enrollment period is

six

months. Enrollment dates are the

first

business day of

May

and

November.

Under the ESPP, we issued

71,499,

77,283,

and

54,932

shares in

2018,

2017

and

2016,

respectively. The weighted-average exercise price per share of the purchase rights exercised during

2018,

2017

and

2016

was

$16.48,

$12.80

and

$14.03,

respectively. As of

December

31,

2018,

279,182

shares of common stock have been issued under the ESPP and

195,818

shares of common stock are available for future issuance.

Stock Option Plans

We currently have

one

stock option plan from which we can grant options and restricted stock awards to employees, officers, directors and consultants. In

December 2007,

the stockholders approved our

2007

Equity Incentive Plan (

“2007

Plan”) at which time a maximum of

150,000

shares of common stock were available for grant. In

May 2010,

June 2011,

May 2014,

May 2015,

June 2016

and

June 2017,

our stockholders approved amendments to our

2007

Plan to increase the maximum number of shares of common stock available for grant by

100,000,

4,500,000,

1,750,000,

4,300,000,

3,000,000

and

5,000,000

shares of common stock, respectively, resulting in an aggregate of

18,800,000

shares of common stock authorized for issuance as of

December 31, 2018.

December 31, 2018,

there were

1,354,280

shares available for future grant under the

2007

Plan. Any shares that are issuable on exercise of options granted that expire, are cancelled or that we receive pursuant to a net exercise of options are available for future grant and issuance.

2014,

2013

and

2012,

we granted options to certain employees outside of our stockholder approved stock option plans. All options to purchase our common stock were granted with an exercise price that equals fair market value of the underlying common stock on the grant dates and expire

later than

ten

years from the date of grant. The options are exercisable in accordance with vesting schedules that generally provide for them to be fully vested and exercisable

four

years after the date of grant, provided, however, that we have also issued stock options awards that are subject to performance vesting requirements. All stock option grants issued outside of our stockholder approved plans have been registered on Form S-

with the SEC.

The following table summarizes the stock option activity:

	Outstanding Options
				Weighted-
				Average
	Number of			Exercise
	Shares			Price
Balance at December 31, 2015		8,434,988		$	13.64
Granted		4,920,661			15.98
Exercised		(798,363	)		8.37
Cancelled		(711,910	)		22.43
Balance at December 31, 2016		11,845,376			14.44
Granted		4,300,621			16.17
Exercised		(1,350,605	)		8.49
Cancelled		(1,332,429	)		20.06
Balance at December 31, 2017		13,462,963			15.03
Granted		4,052,011			26.83
Exercised		(1,529,509	)		11.97
Cancelled		(720,859	)		17.98
Balance at December 31, 2018		15,264,606			18.33

For the year ended

December

31,

2018,

options cancelled (included in the above table) consisted of

667,338

options forfeited with a weighted-average exercise price of

$17.04

and

53,521

options expired with a weighted-average exercise price of

$29.71.

As of

December

31,

2018,

options exercisable have a weighted-average remaining contractual term of

5.3

years. The total intrinsic value of stock option exercises, which is the difference between the exercise price and closing price of our common stock on the date of exercise, during the years ended

December

31,

2018

and

2017

was

$31.4

million and

$9.9

million, respectively. As of

December

31,

2018

and

2017,

the total intrinsic value of options outstanding and exercisable was

$75.7

million and

$35.6

million, respectively.

	Years Ended December 31,
	2018				2017				2016
			Weighted-				Weighted-				Weighted-
			Average				Average				Average
			Exercise				Exercise				Exercise
	Options		Price		Options		Price		Options		Price
Exercisable at end of year		6,523,093	$	14.83		5,446,586	$	13.25		4,356,665	$	11.66
Options vested or expected to vest		14,449,017	$	18.11		12,854,571	$	14.98		11,234,529	$	14.32

Exercise prices and weighted-average remaining contractual lives for the options outstanding as of

December

31,

2018

were:

										Weighted-
				Weighted-						Average
				Average		Weighted-				Exercise
				Remaining		Average				Price of
Options	Range of			Contractual		Exercise		Options		Options
Outstanding	Exercise Prices			Life (in years)		Price		Exercisable		Exercisable
2,635,453	$5.20	–	$9.05		3.03	$	7.99		2,260,453	$	8.12
2,531,622	$9.33	–	$14.20		6.29		12.89		1,406,228		12.66
4,195,066	$14.25	–	$17.00		7.78		16.60		1,512,260		16.54
845,157	$17.05	–	$23.90		7.56		20.52		478,721		20.64
2,860,911	$24.97	–	$24.97		8.94		24.97		—		—
2,196,397	$25.06	–	$39.25		7.42		30.85		865,431		29.71
15,264,606	$5.20	–	$39.25		6.87		18.33		6,523,093		14.83

December

31,

2018,

we had reserved

15,264,606

shares of common stock for future issuance on exercise of outstanding options granted under the

2007

Plan, as well as the non-plan grants.

Valuation and Expense Information

The following table summarizes stock-based compensation expense related to stock-based payment awards granted pursuant to all of our equity compensation arrangements (in thousands):

	December 31,
	2018		2017		2016
Research and development	$	13,689	$	11,312	$	11,316
General and administrative		9,630		9,469		7,402
Sales and marketing		10,048		9,757		7,238
Total stock-based compensation expense	$	33,367	$	30,538	$	25,956

As of

December

31,

2018,

there was

$117.5

million of total unrecognized compensation cost related to non-vested, stock-based payment awards granted under all of our equity compensation plans and all non-plan option grants. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. We expect to recognize this compensation cost over a weighted-average period of

2.8

years.

We estimated the fair value of each option grant and ESPP purchase right on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:

Options:

	December 31,
	2018			2017			2016
Risk-free interest rate		2.8	%		2.1	%		1.7	%
Dividend yield		—	%		—	%		—	%
Volatility		70.4	%		74.0	%		89.1	%
Expected life (years)		6			6			6

ESPP:

	December 31,
	2018			2017			2016
Risk-free interest rate		2.4	%		1.2	%		0.4	%
Dividend yield		—	%		—	%		—	%
Volatility		59.7	%		50.0	%		68.3	%
Expected life (months)		6			6			6

The weighted-average fair value of options granted was

$17.24,

$10.61

and

$11.82

for the years ended

December

31,

2018,

2017

and

2016,

respectively.

The weighted-average fair value of shares purchased through the ESPP was

$9.95,

$4.51

and

$6.10

for the years ended

December

31,

2018,

2017

and

2016,

respectively.

The risk-free interest rate assumption is based on observed interest rates on U.S. Treasury debt securities with maturities close to the expected term of our employee and director stock options and ESPP purchases.

The dividend yield assumption is based on our history and expectation of dividend payouts. We have never paid dividends on our common stock, and we do

not

anticipate paying dividends in the foreseeable future.

We used our historical stock price to estimate volatility.

The expected life of employee and director stock options represents the average of the contractual term of the options and the weighted-average vesting period, as permitted under the simplified method. We have elected to use the simplified method, as we do

not

have enough historical exercise experience to provide a reasonable basis on which to estimate the expected term. The expected life for the ESPP purchase rights is

six

months, which represents the length of each purchase period.

Note 10 - Income Taxes

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Income Tax Disclosure [Text Block]

10 .	Income Taxes

For the years ended

December 31, 2018,

2017

and

2016,

we did

not

record a provision for income taxes due to a full valuation allowance against our deferred tax assets.

The difference between the provision for income taxes and income taxes computed using the effective U.S. federal statutory rate is as follows (in thousands):

	December 31,
	2018			2017			2016
Tax at statutory federal rate	$	(37,557	)	$	(67,145	)	$	(58,868	)
State tax, net of federal benefit		(6,527	)		(6,203	)		2,013
Research and development credits		(4,775	)		(5,962	)		(4,206	)
Stock-based compensation expense		(2,059	)		3,151			2,694
Non-deductible compensation		901			—			1,864
Change in valuation allowance		50,834			3,241			55,173
Impact of the 2017 Tax Act		—			74,361			—
Other		(817	)		(1,443	)		1,330
Provision for income taxes	$	—		$	—		$	—

Deferred income tax assets and liabilities arising from differences between accounting for financial statement purposes and tax purposes, less valuation allowance at year-end are as follows (in thousands):

	December 31,
	2018			2017
Deferred tax assets:
Net operating loss carryforward	$	172,113		$	134,659
Research and development credits		35,670			25,919
Stock-based compensation		11,905			8,633
Other		3,171			2,920
Total gross deferred tax assets		222,859			172,131
Valuation allowance		(222,859	)		(172,131	)
Net deferred tax assets	$	—		$	—

We have established a valuation allowance to offset net deferred tax assets as of

December 31, 2018

and

2017

due to the uncertainty of realizing future tax benefits from such assets.

As of

December 31, 2018,

we had federal, California and other state net operating loss (“NOL”) carryforwards of

$715.3

million,

$122.3

million and

$824.9

million, respectively. The federal NOL carryforwards consist of

$549.7

million generated before

January 1, 2018,

which will begin to expire in

2021

and

$165.6

million that will carryforward indefinitely but are subject to the

80%

taxable income limitation. The state NOL carryforwards will begin to expire in

2028.

As of

December 31, 2018,

we had federal and California state research and development credit carryforwards of

$27.2

million and

$13.3

million, respectively. The federal research and development credit carryforwards will begin to expire in

2022.

The California state credits can be carried forward indefinitely.

Internal Revenue Code (“IRC”) Section

382

and

383

places a limitation on the amount of taxable income that can be offset by NOL and credit carryforwards after a change in control (generally greater than

50%

change in ownership within a

three

-year period) of a loss corporation. California has similar rules. Generally, after a change in control, a loss corporation cannot deduct NOL and credit carryforwards in excess of the IRC Section

382

and

383

limitation. We have performed an IRC Section

382

and

383

analysis and determined there were ownership changes in

2007,

2011,

and

2013.

We are currently in the process of completing the IRC Section

382

and

383

analysis for

2018.

The limitation in the federal and state carryforwards associated with the NOL and credit carryforwards reduce the deferred tax assets, which are further offset by a full valuation allowance. The limitation can result in the expiration of the NOLs and credit carryforwards available as of

December 31, 2018.

We file U.S. and state income tax returns with varying statutes of limitations. The tax years from

1999

2018

remain open to examination due to the carryover of unused NOL carryforwards and tax credits.

The Tax Cuts and Jobs Act (

“2017

Tax Act”) was enacted in

December 2017.

The

2017

Tax Act, among other things, reduces the U.S. federal corporate tax rate from

35%

21%,

effective

January 1, 2018,

requires companies to pay a

one

-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign earnings. We revalued our deferred tax assets as of

December 31, 2017

based on a U.S. federal tax rate of

21%,

which resulted in a reduction to our deferred tax assets of

$74.3

million fully offset by a reduction to the valuation allowance. We were

not

required to pay a

one

-time transition tax on earnings of our foreign subsidiary as the foreign subsidiary has an accumulated deficit. In addition, the Global Intangible Low-taxed Income provision is

not

applicable given the Company’s controlled foreign corporations incurred losses for the year ended

December 31, 2018.

December 2017,

the SEC staff issued Staff Accounting Bulletin

No.

118

(“SAB

118”

), which provides guidance for the tax effects of the

2017

Tax Act. SAB

118

provides a measurement period that should

not

extend beyond

one

year from the Tax Act’s enactment date for companies to complete the accounting under ASC

740.

In accordance with SAB

118,

we must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC

740

is complete. To the extent that our accounting for certain income tax effects of the Tax Act is incomplete, but we are able to determine a reasonable estimate, we must record a provisional estimate in our financial statements. If we cannot determine a provisional estimate to be included in our financial statements, we should continue to apply ASC

740

on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act. We have completed our analysis of the Tax Act’s income tax effects. In accordance with SAB

118,

the Tax Act-related income tax effects that we initially reported as provisional estimates were refined as additional analysis was performed. Our analysis was complete in the

fourth

quarter of

2018

and there was

material impact to our consolidated balance sheets or statements of operations and comprehensive loss.

A reconciliation of our unrecognized tax benefits is as follows (in thousands):

	Year Ended December 31,
	2018		2017		2016
Balance at beginning of year	$	120	$	120	$	120
Additions for tax positions of prior years		—		—		—
Additions based on tax positions related to current year		2,265		—		—
Balance at end of year	$	2,385	$	120	$	120

Due to our valuation allowance, the

$2.4

million of unrecognized tax benefits would

not

affect the effective tax rate, if recognized. It is the Company’s practice to recognize interest and penalties related to income tax matters in income tax expense. As of

December 31, 2018,

we had

accrued interest and penalties related to uncertain tax positions. We do

not

expect any material changes to the estimated amount of liability associated with our uncertain tax positions within the next

months.

Note 11 - Other Income (Expense), Net	12 Months Ended
Note 11 - Other Income (Expense), Net	Dec. 31, 2018
Notes to Financial Statements
Other Nonoperating Income and Expense [Text Block]	1 1 . Other Income (Expense), Net In 2018, we recorded $1.9 million in income to other income (expense), net resulting from the disgorgement of short-swing profits arising from the sales of our common stock by a beneficial owner pursuant to Section 16 (b) of the Securities and Exchange Act of 1934.

Note 12 - Employee Benefit Plan

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Pension and Other Postretirement Benefits Disclosure [Text Block]

Employee Benefit Plan

We have a defined contribution

401

(k) plan (“Plan”) covering substantially all of our employees. In the past

three

calendar years, we made matching cash contributions equal to

50%

of each participant’s contribution during the Plan year up to a maximum amount equal to the lesser of

of each participant’s annual compensation or

$8,250,

$8,100

and

$7,950

for the years ended

December 31, 2018,

2017

and

2016,

respectively. Such amounts were recorded as expense in the corresponding years. We

may

also contribute additional discretionary amounts to the Plan as we determine. For the years ended

December 31, 2018,

2017

and

2016,

we contributed

$0.7

million,

$0.6

million and

$0.6

million, respectively, to the Plan.

discretionary contributions have been made to the Plan since its inception.

Note 13 - Summary of Quarterly Consolidated Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Quarterly Financial Information [Text Block]

Summary of Quarterly

Consolidated

Financial Data (U

naudited)

The following is a summary of the unaudited quarterly results of operations for the years ended

December

31,

2018

and

2017:

	2018
	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	(In thousands, except per share amounts)
Revenues:
Net product sales	$	11,567		$	17,277		$	19,786		$	28,844
Cost of product sales		(3,133	)		(5,231	)		(7,576	)		(11,572	)
Gross Profit		8,434			12,046			12,210			17,272
Operating expenses:
Research and development		39,561			30,159			30,421			39,891
General and administrative		7,028			6,209			7,288			8,738
Sales and marketing		13,835			14,531			16,281			19,957
Loss from operations		(51,990	)		(38,853	)		(41,780	)		(51,314	)
Other income (expense), net		(275	)		183			3,434			1,755
Net loss	$	(52,265	)	$	(38,670	)	$	(38,346	)	$	(49,559	)
Basic and diluted net loss per share	$	(0.81	)	$	(0.54	)	$	(0.49	)	$	(0.63	)

	2017
	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	(In thousands, except per share amounts)
Revenues:
Net product sales	$	3,632		$	8,510		$	8,572		$	10,053
Cost of product sales		(1,186	)		(1,013	)		(1,051	)		(1,338	)
Gross Profit		2,446			7,497			7,521			8,715
Operating expenses:
Research and development		33,384			28,597			28,844			47,757
General and administrative		6,742			6,185			6,462			6,165
Sales and marketing		11,619			14,770			13,529			16,683
Loss from operations		(49,299	)		(42,055	)		(41,314	)		(61,890	)
Other expense, net		(1,030	)		(744	)		(552	)		(600	)
Net loss	$	(50,329	)	$	(42,799	)	$	(41,866	)	$	(62,490	)
Basic and diluted net loss per share	$	(1.00	)	$	(0.80	)	$	(0.77	)	$	(1.09	)

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

March 2015.

Heron Therapeutics, B.V. has

operations and

material assets or liabilities, and there have been

significant transactions related to Heron Therapeutics, B.V. since its inception.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Cash, Cash Equivalents, and Short-Term Investments [Policy Text Block]

Cash,

Cash Equivalents

and Short-Term Investments

Cash and cash equivalents consist of cash and highly liquid investments with contractual maturities of

three

months or less from the original purchase date.

Short-term investments consist of securities with contractual maturities of greater than

three

months to

one

Our bank and investment accounts have been placed under control agreements in accordance with our Senior Secured Convertible Notes (“Convertible Notes”) (see Note

Fair Value Measurement, Policy [Policy Text Block]

Fair Value of Financial Instruments

A company

may

not

be recognized at inception and non-cash warranty obligations where a warrantor is permitted to pay a

third

not

apply the fair value option to our financial assets and liabilities.

). Our Convertible Notes outstanding at

December

31,

2018

not

have a readily available ascertainable market value, however, the carrying value is considered to approximate its fair value.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

may

be in excess of insured limits. We

may

The following table includes the percentage of net product sales and accounts receivable balances for our

three

major Customers, each of which comprised

10%

or more of our net product sales:

	Net Product Sales			Accounts Receivable
	Year Ended December 31 , 2018			As of December 31 , 2018

Customer A		41.7	%		38.7	%
Customer B		34.9	%		46.1	%
Customer C		22.5	%		14.8	%
Total		99.1	%		99.6	%

Receivables, Policy [Policy Text Block]

Accounts Receivable, Net

) our historical experience with collections and write-offs; (

) the credit quality of our Customers and any recent or anticipated changes thereto; and (

) the outstanding balances and past due amounts from our Customers.

We offered extended payment terms to our Customers in connection with our product launches of SUSTOL and CINVANTI in

October 2016

and

January 2018,

respectively, in anticipation of the timing in reimbursement by government and commercial payers. Effective

January 2018,

we shortened payment terms to certain of our SUSTOL Customers. As of

December 31, 2018,

extended payment terms given to our Customers were evaluated in accordance with GAAP and did

not

impact the collectability of accounts receivables.

As of

December 31, 2018,

we determined that an allowance for doubtful accounts was

not

required. For the year ended

December 31, 2018,

we did

not

write off any accounts receivable balances.

Inventory, Policy [Policy Text Block]

Inventory

Inventory is stated at the lower of cost or estimated net realizable value on a

first

-in,

first

may

be required, which would be recorded as cost of product sales.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets (generally

five

years). Leasehold improvements are stated at cost and amortized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term.

Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

May 2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

No.

2014

09,

Revenue from Contracts with Customers

(“Topic

606”

). Topic

606

is effective for fiscal years beginning after

December 15, 2017,

including interim periods within those fiscal years. Accordingly, in the

first

quarter of

2018,

we adopted Topic

606

using the modified retrospective approach. Under this approach, incremental disclosures are provided to present each financial statement line item for

2018

under the prior standard. As a result of the adoption of Topic

606,

we recorded a cumulative adjustment to accumulated deficit of

$1.6

million on

January 1, 2018.

This adjustment reflects the acceleration of

$2.9

million in gross product sales less

$1.1

million in product sales allowances and

$0.2

million in cost of product sales (see Note

Clinical Trial Accruals [Policy Text Block]

Accrued Clinical Liabilities

may

not

Research and Development Expense, Policy [Policy Text Block]

Research and Development Expense

Legal Costs, Policy [Policy Text Block]

Patent Costs

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock-Based Compensation Expense

Warrants Issued in Equity Financings [Policy Text Block]

Warrants

Income Tax, Policy [Policy Text Block]

Income Taxes

We recognize the impact of a tax position in our consolidated financial statements if the position is more likely than

not

affect our effective tax rate, since we maintain a full valuation allowance against our deferred tax assets (see Note

). We recognize interest and penalties related to income tax matters in income tax expense.

Comprehensive Income, Policy [Policy Text Block]

Comprehensive

Loss

Earnings Per Share, Policy [Policy Text Block]

Net Loss

per Share

Because we have incurred a net loss for all periods presented in the consolidated statements of operations and comprehensive loss, the following common stock equivalents were

not

included in the computation of net loss per share because their effect would be anti-dilutive (in thousands):

	December 31 ,
	2018		2017		2016

Stock options outstanding		15,265		13,463		11,845
Warrants outstanding		640		620		600
Shares of common stock underlying Convertible Notes outstanding		8,473		7,983		7,521

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

Recently Adopted

May 2017,

the FASB issued ASU

No.

2017

09,

Compensation – Stock Compensation: Scope of Modification Accounting

(“ASU

2017

09”

The amendments in ASU

2017

provide guidance about which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting in Topic

718.

In the

first

quarter of

2018,

we adopted the provisions of ASU

2017

09,

which did

not

have a material impact on our results of operations or financial condition.

Not

Yet Adopted

February 2016,

the FASB issued ASU

No.

2016

02,

Leases (Topic

842

)

(“ASU

2016

02”

which provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. In

July 2018,

the FASB issued ASU

No.

2018

11,

Leases (Topic

842

): Targeted Improvements

and ASU

No.

2018

10,

Codification Improvements to Topic

842,

Leases

. ASU

2016

and the subsequent modifications are identified as “ASC

842.”

ASC

842

requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or

not

twelve

months, regardless of classification. Leases with a term of

twelve

months or less will be accounted for similar to existing guidance for operating leases. ASC

842

is effective for fiscal years beginning after

December 15, 2018,

including interim periods within those fiscal years. We adopted the provisions of ASU

2016

January 1, 2019

using the alternative modified transition method. We are still in the process of finalizing our assessment of the impact of ASC

842

842.

August 2018,

the FASB issued ASU

No.

2018

13,

Fair Value Measurement (Topic

820

) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement

(“ASU

2018

13”

), which is designed to improve the effectiveness of disclosures by removing, modifying and adding disclosures related to fair value measurements. ASU

2018

is effective for fiscal years beginning after

December 15, 2019,

including interim periods within those fiscal years. Early adoption is permitted. We plan to adopt the provisions of ASU

2018

in the

first

quarter of

2020,

and we are currently evaluating the impact on our consolidated financial statements.

Note 2 - Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

	Net Product Sales			Accounts Receivable
	Year Ended December 31 , 2018			As of December 31 , 2018

Customer A		41.7	%		38.7	%
Customer B		34.9	%		46.1	%
Customer C		22.5	%		14.8	%
Total		99.1	%		99.6	%

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	December 31 ,
	2018		2017		2016

Stock options outstanding		15,265		13,463		11,845
Warrants outstanding		640		620		600
Shares of common stock underlying Convertible Notes outstanding		8,473		7,983		7,521

Note 3 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

			Fair Value Measurements at Reporting Date Using
			Quoted Prices in		Significant
			Active Markets		Other		Significant
	Balance at		for Identical		Observable		Unobservable
	December 31,		Assets		Inputs		Inputs
	2018		(Level 1)		(Level 2)		(Level 3)
Money market funds	$	13,874	$	13,874	$	—	$	—
U.S. treasury bills and government agency obligations		59,741		59,741		—		—
U.S. corporate debt securities		59,087		—		59,087		—
Foreign corporate debt securities		5,046		—		5,046		—
U.S. commercial paper		61,885		—		61,885		—
Foreign commercial paper		123,861		—		123,861		—
Total	$	323,494	$	73,615	$	249,879	$	—

			Fair Value Measurements at Reporting Date Using
			Quoted Prices in		Significant
			Active Markets		Other		Significant
	Balance at		for Identical		Observable		Unobservable
	December 31 ,		Assets		Inputs		Inputs
	2017		(Level 1)		(Level 2)		(Level 3)
Money market funds	$	91,386	$	91,386	$	—	$	—
U.S. corporate debt securities		17,520		—		17,520		—
U.S. commercial paper		39,863		—		39,863		—
Foreign commercial paper		19,854		—		19,854		—
Total	$	168,623	$	91,386	$	77,237	$	—

Note 4 - Balance Sheet Details (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Available-for-sale Securities [Table Text Block]

	December 31, 201 8
			Gross		Gross
	Amortized		Unrealized		Unrealized			Estimated
	Cost		Gains		Losses			Fair Value
U.S. treasury bills and government agency obligations	$	59,747	$	—	$	(6	)	$	59,741
U.S. corporate debt		59,164		—		(77	)		59,087
Foreign corporate debt		5,041		5		—			5,046
U.S. commercial paper		52,800		—		—			52,800
Foreign commercial paper		123,870		—		(9	)		123,861
Total	$	300,622	$	5	$	(92	)	$	300,535

	December 31, 201 7
			Gross		Gross
	Amortized		Unrealized		Unrealized			Estimated
	Cost		Gains		Losses			Fair Value
U.S. corporate debt securities	$	13,003	$	—	$	(10	)	$	12,993
U.S. commercial paper		4,929		—		—			4,929
Foreign commercial paper		9,874		—		—			9,874
Total	$	27,806	$	—	$	(10	)	$	27,796

Schedule of Inventory, Current [Table Text Block]

	December 31,
	2018		2017
Raw materials	$	10,112	$	2,754
Work in process		20,604		4,166
Finished goods		8,316		3,188
Total inventory	$	39,032	$	10,108

Property, Plant and Equipment [Table Text Block]

	December 31,
	2018			2017
Scientific equipment	$	18,077		$	9,742
Leasehold improvements		1,783			1,654
Computer equipment and software		1,190			1,420
Furniture, fixtures and office equipment		1,722			1,024
Property and equipment, gross		22,772			13,840
Less: accumulated depreciation and amortization		(8,095	)		(7,859	)
Property and equipment, net	$	14,677		$	5,981

Schedule of Accrued Liabilities [Table Text Block]

	December 31,
	20 18		2017
Accrued employee salaries and benefits	$	2,330	$	1,292
Accrued bonuses		9,139		5,044
Accrued vacation		1,928		1,438
Accrued expenses for realignment (see Note 7)		—		1,086
Total accrued payroll and employee liabilities	$	13,397	$	8,860

	December 31,
	2018		2017
Accrued product sales allowances	$	25,503	$	9,319
Accrued consulting and professional fees		5,768		6,869
Deferred rent		780		651
Accrued accounts payable		224		148
Other accrued liabilities		440		188
Total other accrued liabilities	$	32,715	$	17,175

Note 5 - Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]

	As Reported Under Topic 605			Effect of Change			As Adjusted Under Topic 606

Inventory	$	10,108		$	(198	)	$	9,910
Other accrued liabilities		17,175			991			18,166
Deferred revenue		2,763			(2,763	)		—
Accumulated deficit		(783,455	)		1,574			(781,881	)

	As Reported Under Topic 606			Effect of Change			As Calculated Under Topic 605

Consolidated Balance Sheet as of December 31, 2018:
Inventory	$	39,032		$	2,181		$	41,213
Other accrued liabilities		32,715			(7,195	)		25,520
Deferred revenue		—			14,010			14,010
Accumulated deficit		(960,721	)		(4,634	)		(965,355	)

Consolidated Statement of Operations for the Year Ended December 31 , 2018 :
Net product sales	$	77,474		$	(5,043	)	$	72,431
Cost of product sales		27,512			(1,983	)		25,529
Loss from operations		(183,937	)		(3,060	)		(186,997	)
Net loss		(178,840	)		(3,060	)		(181,900	)
Basic and diluted net loss per share		(2.44	)		(0.05	)		(2.49	)

Consolidated Statement of Cash Flows for the Year Ended December 31 , 2018 :
Net loss	$	(178,840	)	$	(3,060	)	$	(181,900	)
Adjustments to reconcile net loss to net cash used in operating activities:
Inventory		(29,122	)		(1,983	)		(31,105	)
Other accrued liabilities		14,941			(6,204	)		8,737
Deferred revenue		—			11,247			11,247

Valuation Allowances and Reserves [Table Text Block]

	Product Returns			Distributor Fees			Discounts, Rebates and Administrative Fees			Total

Balance at December 31, 2017	$	521		$	580		$	8,218		$	9,319
Provision		464			7,555			58,504			66,523
Payments/credits		(38	)		(5,322	)		(44,979	)		(50,339	)
Balance at December 31, 2018	$	947		$	2,813		$	21,743		$	25,503

Note 6 - Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

Year ended December 31:
2019	$	3,195
2020		2,722
2021		2,801
2022		2,883
2023		2,967
Thereafter		3,274
Total future minimum lease payments	$	17,842

Note 9 - Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Common Stock Reserved for Future Issuance [Table Text Block]

	Number of Shares
Stock options outstanding		15,264,606
Stock options available for grant		1,354,280
Employee stock purchase plan		195,818
Warrants outstanding		640,164
Shares of common stock underlying Convertible Notes outstanding (see Note 8)		8,472,820
Total shares reserved for future issuance		25,927,688

Share-based Compensation, Stock Options, Activity [Table Text Block]

	Outstanding Options
				Weighted-
				Average
	Number of			Exercise
	Shares			Price
Balance at December 31, 2015		8,434,988		$	13.64
Granted		4,920,661			15.98
Exercised		(798,363	)		8.37
Cancelled		(711,910	)		22.43
Balance at December 31, 2016		11,845,376			14.44
Granted		4,300,621			16.17
Exercised		(1,350,605	)		8.49
Cancelled		(1,332,429	)		20.06
Balance at December 31, 2017		13,462,963			15.03
Granted		4,052,011			26.83
Exercised		(1,529,509	)		11.97
Cancelled		(720,859	)		17.98
Balance at December 31, 2018		15,264,606			18.33

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]

	Years Ended December 31,
	2018				2017				2016
			Weighted-				Weighted-				Weighted-
			Average				Average				Average
			Exercise				Exercise				Exercise
	Options		Price		Options		Price		Options		Price
Exercisable at end of year		6,523,093	$	14.83		5,446,586	$	13.25		4,356,665	$	11.66
Options vested or expected to vest		14,449,017	$	18.11		12,854,571	$	14.98		11,234,529	$	14.32

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

										Weighted-
				Weighted-						Average
				Average		Weighted-				Exercise
				Remaining		Average				Price of
Options	Range of			Contractual		Exercise		Options		Options
Outstanding	Exercise Prices			Life (in years)		Price		Exercisable		Exercisable
2,635,453	$5.20	–	$9.05		3.03	$	7.99		2,260,453	$	8.12
2,531,622	$9.33	–	$14.20		6.29		12.89		1,406,228		12.66
4,195,066	$14.25	–	$17.00		7.78		16.60		1,512,260		16.54
845,157	$17.05	–	$23.90		7.56		20.52		478,721		20.64
2,860,911	$24.97	–	$24.97		8.94		24.97		—		—
2,196,397	$25.06	–	$39.25		7.42		30.85		865,431		29.71
15,264,606	$5.20	–	$39.25		6.87		18.33		6,523,093		14.83

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	December 31,
	2018		2017		2016
Research and development	$	13,689	$	11,312	$	11,316
General and administrative		9,630		9,469		7,402
Sales and marketing		10,048		9,757		7,238
Total stock-based compensation expense	$	33,367	$	30,538	$	25,956

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	December 31,
	2018			2017			2016
Risk-free interest rate		2.8	%		2.1	%		1.7	%
Dividend yield		—	%		—	%		—	%
Volatility		70.4	%		74.0	%		89.1	%
Expected life (years)		6			6			6

	December 31,
	2018			2017			2016
Risk-free interest rate		2.4	%		1.2	%		0.4	%
Dividend yield		—	%		—	%		—	%
Volatility		59.7	%		50.0	%		68.3	%
Expected life (months)		6			6			6

Note 10 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	December 31,
	2018			2017			2016
Tax at statutory federal rate	$	(37,557	)	$	(67,145	)	$	(58,868	)
State tax, net of federal benefit		(6,527	)		(6,203	)		2,013
Research and development credits		(4,775	)		(5,962	)		(4,206	)
Stock-based compensation expense		(2,059	)		3,151			2,694
Non-deductible compensation		901			—			1,864
Change in valuation allowance		50,834			3,241			55,173
Impact of the 2017 Tax Act		—			74,361			—
Other		(817	)		(1,443	)		1,330
Provision for income taxes	$	—		$	—		$	—

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	December 31,
	2018			2017
Deferred tax assets:
Net operating loss carryforward	$	172,113		$	134,659
Research and development credits		35,670			25,919
Stock-based compensation		11,905			8,633
Other		3,171			2,920
Total gross deferred tax assets		222,859			172,131
Valuation allowance		(222,859	)		(172,131	)
Net deferred tax assets	$	—		$	—

Summary of Income Tax Contingencies [Table Text Block]

	Year Ended December 31,
	2018		2017		2016
Balance at beginning of year	$	120	$	120	$	120
Additions for tax positions of prior years		—		—		—
Additions based on tax positions related to current year		2,265		—		—
Balance at end of year	$	2,385	$	120	$	120

Note 13 - Summary of Quarterly Consolidated Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Quarterly Financial Information [Table Text Block]

	2018
	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	(In thousands, except per share amounts)
Revenues:
Net product sales	$	11,567		$	17,277		$	19,786		$	28,844
Cost of product sales		(3,133	)		(5,231	)		(7,576	)		(11,572	)
Gross Profit		8,434			12,046			12,210			17,272
Operating expenses:
Research and development		39,561			30,159			30,421			39,891
General and administrative		7,028			6,209			7,288			8,738
Sales and marketing		13,835			14,531			16,281			19,957
Loss from operations		(51,990	)		(38,853	)		(41,780	)		(51,314	)
Other income (expense), net		(275	)		183			3,434			1,755
Net loss	$	(52,265	)	$	(38,670	)	$	(38,346	)	$	(49,559	)
Basic and diluted net loss per share	$	(0.81	)	$	(0.54	)	$	(0.49	)	$	(0.63	)

	2017
	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	(In thousands, except per share amounts)
Revenues:
Net product sales	$	3,632		$	8,510		$	8,572		$	10,053
Cost of product sales		(1,186	)		(1,013	)		(1,051	)		(1,338	)
Gross Profit		2,446			7,497			7,521			8,715
Operating expenses:
Research and development		33,384			28,597			28,844			47,757
General and administrative		6,742			6,185			6,462			6,165
Sales and marketing		11,619			14,770			13,529			16,683
Loss from operations		(49,299	)		(42,055	)		(41,314	)		(61,890	)
Other expense, net		(1,030	)		(744	)		(552	)		(600	)
Net loss	$	(50,329	)	$	(42,799	)	$	(41,866	)	$	(62,490	)
Basic and diluted net loss per share	$	(1.00	)	$	(0.80	)	$	(0.77	)	$	(1.09	)

Note 1 - Organization and Business (Details Textual) $ in Millions	Dec. 31, 2018 USD ($)
Cash, Cash Equivalents, and Short-term Investments, Total	$ 332.4

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands		3 Months Ended								12 Months Ended
	Jan. 01, 2018	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cumulative Effect of New Accounting Principle in Period of Adoption		$ 1,574								$ 1,574
Revenue from Contract with Customer, Including Assessed Tax		28,844	$ 19,786	$ 17,277	$ 11,567	$ 10,053	$ 8,572	$ 8,510	$ 3,632	77,474	$ 30,767	$ 1,279
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance		25,503				9,319				25,503	9,319
Cost of Goods and Services Sold, Total		11,572	$ 7,576	$ 5,231	$ 3,133	$ 1,338	$ 1,051	$ 1,013	$ 1,186	27,512	$ 4,588	$ 35
Accounting Standards Update 2014-09 [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 2,900
Cost of Goods and Services Sold, Total	200
Accounting Standards Update 2014-09 [Member] \| Product Sales Allowance [Member]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance	1,100
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption		$ 1,574								$ 1,574
Retained Earnings [Member] \| Accounting Standards Update 2014-09 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	$ 1,600

Note 2 - Summary of Significant Accounting Policies - Percentage of Net Product Sales and Accounts Receivable Balance (Details) - Customer Concentration Risk [Member]	6 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2018
Sales Revenue, Net [Member]
Concentration risk percentage	99.10%
Sales Revenue, Net [Member] \| Largest Customer [Member]
Concentration risk percentage	41.70%
Sales Revenue, Net [Member] \| Second Largest Customer [Member]
Concentration risk percentage	34.90%
Sales Revenue, Net [Member] \| Third Largest Customer [Member]
Concentration risk percentage	22.50%
Accounts Receivable [Member]
Concentration risk percentage		99.60%
Accounts Receivable [Member] \| Largest Customer [Member]
Concentration risk percentage		38.70%
Accounts Receivable [Member] \| Second Largest Customer [Member]
Concentration risk percentage		46.10%
Accounts Receivable [Member] \| Third Largest Customer [Member]
Concentration risk percentage		14.80%

Note 2 - Summary of Significant Accounting Policies - Securities Excluded From Calculation of Diluted Earnings Per Share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Stock Option [Member]
Shares excluded (in shares)	15,265	13,463	11,845
Warrant [Member]
Shares excluded (in shares)	640	620	600
Convertible Debt Securities [Member]
Shares excluded (in shares)	8,473	7,983	7,521

Note 3 - Fair Value Measurements (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash Equivalents, at Carrying Value, Total	$ 9,100,000	$ 49,400,000
Available-for-sale Securities, Current, Total	300,535,000	27,796,000
Debt Securities, Available-for-sale, Realized Gain (Loss), Total	77,000	7,000	$ 23,000
Available-for-sale Securities, Gross Realized Gains	0	0	0
Available-for-sale Securities, Gross Realized Losses	$ 0	$ 0	$ 0

Note 3 - Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Total	$ 323,494	$ 168,623
Foreign Commercial Paper [Member]
Available-for-sale securities	123,861	19,854
US Treasury Securities [Member]
Available-for-sale securities	59,741
Debt Security, Corporate, US [Member]
Available-for-sale securities	59,087	17,520
United States Commercial Paper [Member]
Available-for-sale securities	61,885	39,863
Debt Security, Corporate, Non-US [Member]
Available-for-sale securities	5,046
Fair Value, Inputs, Level 1 [Member]
Total	73,615	91,386
Fair Value, Inputs, Level 1 [Member] \| US Treasury Securities [Member]
Available-for-sale securities	59,741
Fair Value, Inputs, Level 1 [Member] \| Debt Security, Corporate, US [Member]
Available-for-sale securities
Fair Value, Inputs, Level 1 [Member] \| United States Commercial Paper [Member]
Available-for-sale securities
Fair Value, Inputs, Level 1 [Member] \| Debt Security, Corporate, Non-US [Member]
Available-for-sale securities
Fair Value, Inputs, Level 1 [Member] \| Foreign Commercial Paper [Member]
Available-for-sale securities
Fair Value, Inputs, Level 2 [Member]
Total	249,879	77,237
Fair Value, Inputs, Level 2 [Member] \| US Treasury Securities [Member]
Available-for-sale securities
Fair Value, Inputs, Level 2 [Member] \| Debt Security, Corporate, US [Member]
Available-for-sale securities	59,087	17,520
Fair Value, Inputs, Level 2 [Member] \| United States Commercial Paper [Member]
Available-for-sale securities	61,885	39,863
Fair Value, Inputs, Level 2 [Member] \| Debt Security, Corporate, Non-US [Member]
Available-for-sale securities	5,046
Fair Value, Inputs, Level 2 [Member] \| Foreign Commercial Paper [Member]
Available-for-sale securities	123,861	19,854
Fair Value, Inputs, Level 3 [Member]
Total
Fair Value, Inputs, Level 3 [Member] \| US Treasury Securities [Member]
Available-for-sale securities
Fair Value, Inputs, Level 3 [Member] \| Debt Security, Corporate, US [Member]
Available-for-sale securities
Fair Value, Inputs, Level 3 [Member] \| United States Commercial Paper [Member]
Available-for-sale securities
Fair Value, Inputs, Level 3 [Member] \| Debt Security, Corporate, Non-US [Member]
Available-for-sale securities
Fair Value, Inputs, Level 3 [Member] \| Foreign Commercial Paper [Member]
Available-for-sale securities
Money Market Funds [Member]
Available-for-sale securities	13,874	91,386
Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]
Available-for-sale securities	13,874	91,386
Money Market Funds [Member] \| Fair Value, Inputs, Level 2 [Member]
Available-for-sale securities
Money Market Funds [Member] \| Fair Value, Inputs, Level 3 [Member]
Available-for-sale securities

Note 4 - Balance Sheet Details (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jan. 01, 2018
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total	$ 0	$ 0
Inventory, Net, Total	39,032	10,108		$ 9,910
Depreciation, Total	1,500	1,500	$ 1,100
Construction in Progress, Gross	10,300	2,000
SUSTOL [Member]
Inventory, Net, Total	6,700	7,100
CINVANTI [Member]
Inventory, Net, Total	$ 32,300	$ 3,000

Note 4 - Balance Sheet Details - Available-for-sale Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Available-for-sale securities, amortized cost	$ 300,622	$ 27,806
Available-for-sale securities, gross unrealized gains	5
Available-for-sale securities, gross unrealized losses	(92)	(10)
Available-for-sale securities, current	300,535	27,796
US Treasury Securities [Member]
Available-for-sale securities, amortized cost	59,747
Available-for-sale securities, gross unrealized gains
Available-for-sale securities, gross unrealized losses	(6)
Available-for-sale securities, current	59,741
Debt Security, Corporate, US [Member]
Available-for-sale securities, amortized cost	59,164	13,003
Available-for-sale securities, gross unrealized gains
Available-for-sale securities, gross unrealized losses	(77)	(10)
Available-for-sale securities, current	59,087	12,993
United States Commercial Paper [Member]
Available-for-sale securities, amortized cost	52,800	4,929
Available-for-sale securities, gross unrealized losses
Available-for-sale securities, current	52,800	4,929
Debt Security, Corporate, Non-US [Member]
Available-for-sale securities, amortized cost	5,041
Available-for-sale securities, gross unrealized gains	5
Available-for-sale securities, gross unrealized losses
Available-for-sale securities, current	5,046
Foreign Commercial Paper [Member]
Available-for-sale securities, amortized cost	123,870	9,874
Available-for-sale securities, gross unrealized losses	(9)
Available-for-sale securities, current	$ 123,861	$ 9,874

Note 4 - Balance Sheet Details - Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Raw materials	$ 10,112		$ 2,754
Work in process	20,604		4,166
Finished goods	8,316		3,188
Total inventory	$ 39,032	$ 9,910	$ 10,108

Note 4 - Balance Sheet Details - Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property and equipment, gross	$ 22,772	$ 13,840
Less: accumulated depreciation and amortization	(8,095)	(7,859)
Property and equipment, gross	14,677	5,981
Equipment [Member]
Property and equipment, gross	18,077	9,742
Leasehold Improvements [Member]
Property and equipment, gross	1,783	1,654
Computer Equipment [Member]
Property and equipment, gross	1,190	1,420
Furniture and Fixtures [Member]
Property and equipment, gross	$ 1,722	$ 1,024

Note 4 - Balance Sheet Details - Accrued Payroll, Employee Liabilities, and Other Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Accrued employee salaries and benefits	$ 2,330		$ 1,292
Accrued bonuses	9,139		5,044
Accrued vacation	1,928		1,438
Accrued expenses for realignment (see Note 7)			1,086
Total accrued payroll and employee liabilities	13,397		8,860
Accrued product sales allowances	25,503		9,319
Accrued consulting and professional fees	5,768		6,869
Deferred rent	780		651
Accrued accounts payable	224		148
Other accrued liabilities	440		188
Total other accrued liabilities	$ 32,715	$ 18,166	$ 17,175

Note 5 - Revenue Recognition - Adoption of Topic 606 (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended								12 Months Ended
	Jan. 01, 2018	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Inventory	$ 9,910	$ 39,032				$ 10,108				$ 39,032	$ 10,108
Other accrued liabilities	18,166	32,715				17,175				32,715	17,175
Deferred revenue						2,763					2,763
Accumulated deficit	(781,881)	(960,721)				(783,455)				(960,721)	(783,455)
Other accrued liabilities	18,166	32,715				17,175				32,715	17,175
Accumulated deficit	(781,881)	(960,721)				(783,455)				(960,721)	(783,455)
Net product sales		28,844	$ 19,786	$ 17,277	$ 11,567	10,053	$ 8,572	$ 8,510	$ 3,632	77,474	30,767	$ 1,279
Cost of product sales		11,572	7,576	5,231	3,133	1,338	1,051	1,013	1,186	27,512	4,588	35
Loss from operations										(183,937)	(194,558)	(170,915)
Net loss		$ (49,559)	$ (38,346)	$ (38,670)	$ (52,265)	$ (62,490)	$ (41,866)	$ (42,799)	$ (50,329)	$ (178,840)	$ (197,484)	$ (173,143)
Basic and diluted net loss per share (in dollars per share)		$ (0.63)	$ (0.49)	$ (0.54)	$ (0.81)	$ (1.09)	$ (0.77)	$ (0.80)	$ (1)	$ (2.44)	$ (3.65)	$ (4.56)
Inventory										$ (29,122)	$ (4,768)	$ (5,340)
Other accrued liabilities										14,941	11,482	2,482
Deferred revenue											$ 1,664	$ 1,099
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Inventory		$ 41,213								41,213
Other accrued liabilities		25,520								25,520
Deferred revenue		14,010								14,010
Accumulated deficit		(965,355)								(965,355)
Other accrued liabilities		25,520								25,520
Accumulated deficit		(965,355)								(965,355)
Net product sales										72,431
Cost of product sales										25,529
Loss from operations										(186,997)
Net loss										$ (181,900)
Basic and diluted net loss per share (in dollars per share)										$ (2.49)
Inventory										$ (31,105)
Other accrued liabilities										8,737
Deferred revenue										11,247
Accounting Standards Update 2014-09 [Member]
Inventory	(198)
Other accrued liabilities	991
Deferred revenue	(2,763)
Accumulated deficit	1,574
Other accrued liabilities	991
Accumulated deficit	1,574
Net product sales	2,900
Cost of product sales	$ 200
Accounting Standards Update 2014-09 [Member] \| Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Inventory		2,181								2,181
Other accrued liabilities		(7,195)								(7,195)
Deferred revenue		14,010								14,010
Accumulated deficit		(4,634)								(4,634)
Other accrued liabilities		(7,195)								(7,195)
Accumulated deficit		$ (4,634)								(4,634)
Net product sales										(5,043)
Cost of product sales										(1,983)
Loss from operations										(3,060)
Net loss										$ (3,060)
Basic and diluted net loss per share (in dollars per share)										$ (0.05)
Inventory										$ (1,983)
Other accrued liabilities										(6,204)
Deferred revenue										$ 11,247

Note 5 - Revenue Recognition - Summary of Product Sales Allowance (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)
Balance	$ 9,319
Provision	66,523
Payments/credits	(50,339)
Balance	25,503
Allowance for Sales Returns 1 [Member]
Balance	521
Provision	464
Payments/credits	(38)
Balance	947
Allowance for Distributor Fees [Member]
Balance	580
Provision	7,555
Payments/credits	(5,322)
Balance	2,813
Allowance for Rebates and Chargebacks [Member]
Balance	8,218
Provision	58,504
Payments/credits	(44,979)
Balance	$ 21,743

Note 6 - Commitments and Contingencies (Details Textual) $ in Millions	12 Months Ended
	Dec. 31, 2018 USD ($) ft²	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	May 31, 2018 ft²
Operating Leases, Rent Expense, Total \| $	$ 3.2	$ 3.1	$ 2.1
San Diego [Member]
Area of Real Estate Property	28,275			23,873
Lessee, Operating Lease, Renewal Term	5 years
Redwood City [Member]
Area of Real Estate Property	26,067
Jersey City [Member]
Area of Real Estate Property	1,898

Note 6 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2018 USD ($)
2019	$ 3,195
2020	2,722
2021	2,801
2022	2,883
2023	2,967
Thereafter	3,274
Total future minimum lease payments	$ 17,842

Note 7 - Realignment of Goals and Objectives and New Development Focus (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2018
Restructuring and Related Cost, Expected Cost, Total		$ 9.4
Restructuring Plan [Member] \| General and Administrative Expense [Member]
Restructuring Charges, Total	$ 0.5
Restructuring Plan [Member] \| Employee Severance [Member]
Restructuring and Related Cost, Expected Cost, Total		5.5
Restructuring Plan [Member] \| Accelerated Non-Cash Stock Option Expense [Member]
Restructuring and Related Cost, Expected Cost, Total		$ 3.9

Note 8 - Secured Notes to Related Party (Details Textual) - USD ($)				1 Months Ended			12 Months Ended
	Aug. 05, 2016	Aug. 02, 2016	Jul. 29, 2011	Aug. 31, 2018	Aug. 31, 2016	Apr. 30, 2011	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Convertible Debt Issuable in Connection with Private Placement						$ 4,500,000
Proceeds from Convertible Debt						$ 4,300,000
Amortization of Debt Discount (Premium)							$ 890,000	$ 773,000	$ 689,000
Convertible Notes Payable, Related Parties, Current							4,574,000	3,684,000
Interest Expense, Total							2,672,000	3,937,000	2,664,000
Repayments of Long-term Debt, Total							25,000,000	25,000,000
Interest Paid, Excluding Capitalized Interest, Operating Activities							1,183,000	2,789,000	1,622,000
Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage						6.00%
Debt Instrument Conversion Ratio Multiple of Principal						$ 1,000
Beneficial Ownership after Conversion						9.99%
Notice Period Associated with Beneficial Ownership Percentage Limitation Convertible Notes						61 days
Common Shares Registered for Resale in Connection with Convertible Notes			3,500,000
Debt Instrument, Term						10 years
Paid-in-Kind Interest								400,000
Debt Instrument, Increase (Decrease), Other, Net								400,000
Amortization of Debt Discount (Premium)							900,000	800,000	700,000
Debt Instrument, Face Amount							6,800,000
Debt Instrument, Unamortized Discount, Total							$ 2,200,000
Debt Instrument, Convertible, Number Shares of Equity Insturments							8,500,000
Interest Expense, Debt, Excluding Amortization							$ 400,000	400,000	$ 400,000
Convertible Debt [Member] \| Common Stock [Member]
Debt Instrument Conversion Ratio Shares						1,250
Term Loan [Member] \| Tang Capital [Member]
Debt Instrument, Interest Rate, Stated Percentage					8.00%
Debt Instrument, Term					2 years
Debt Agreement, Maximum Borrowing Capacity					$ 100,000,000
Proceeds from Issuance of Long-term Debt, Total	$ 50,000,000
Proceeds from Issuance of Long-term Debt, Subject to Achievement of Corporate Milestone		$ 50,000,000
Debt Instrument, Fee Amount		$ 0
Debt Instrument, Number of Warrants		0
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 0
Interest Expense, Total							1,200,000	$ 2,800,000
Repayments of Long-term Debt, Total				$ 25,000,000
Interest Paid, Excluding Capitalized Interest, Operating Activities				$ 200,000
Long-term Debt, Total							$ 0

Note 9 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended													12 Months Ended
	Jun. 30, 2018	Apr. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Jan. 31, 2017	Jun. 30, 2016	May 31, 2015	May 30, 2015	May 31, 2014	Jun. 30, 2011	May 31, 2010	May 31, 2009	Dec. 31, 2007	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2014
Proceeds from Issuance of Common Stock	$ 194.4	$ 168.7	$ 142.6		$ 163.7
Class of Warrant or Right, Number of Securities Called by Warrants or Rights														640,164
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price														$ 11.97	$ 8.49	$ 8.37
Common Stock, Shares, Issued, Total			64,609,000											78,174,000	64,609,000
Common Stock, Capital Shares Reserved for Future Issuance														25,927,688
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant														1,354,280
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period														10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period														4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period														667,338
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price														$ 17.04
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period														53,521
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price														$ 29.71
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term														5 years 109 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value														$ 31.4	$ 9.9
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value			$ 35.6											$ 75.7	$ 35.6
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options, Ending Balance														15,264,606
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized				200,000		100,000		100,000	25,000	25,000		10,000	5,000	475,000
Share-based Compensation Arrangement by Share-based Payment Award Maximum Employee Earnings with held to Purchase Common Stock Percent														10.00%
Share-based Compensation Arrangement by Share-based Payment Award Discount on Stock Price														85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period														71,499	77,283	54,932
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price														$ 16.48	$ 12.80	$ 14.03
Common Stock, Shares, Issued, Total														279,182
Common Stock, Capital Shares Reserved for Future Issuance														195,818
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total														$ 117.5
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition														2 years 292 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value														$ 17.24	10.61	11.82
Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted-average Fair Value Price of Shares Purchased			$ 4.51											$ 9.95	$ 4.51	$ 6.10
Equity Incentive Plan 2007 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized				5,000,000		3,000,000	4,300,000		1,750,000	4,500,000	100,000			18,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized													150,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant														1,354,280
Pre-funded Warrants[Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																	600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																	$ 0.01
Class of Warrant or Right, Exercised During Period															4,426
Class of Warrant or Right, Outstanding														595,574
Common Stock [Member]
Stock Issued During Period, Shares, New Issues	5,100,000	6,900,000	9,700,000		14,100,000									11,963,000	23,822,000
Share Price	$ 39.50	$ 26	$ 15.50		$ 12.20										$ 15.50
Payments of Stock Issuance Costs	$ 5.6	$ 10.7	$ 7.4		$ 8.8
Stock Issued During Period, Shares, Warrants Exercised															4,000	2,396,000
Common Stock [Member] \| Pre-funded Warrants[Member]
Stock Issued During Period, Shares, Warrants Exercised															4,423

Note 9 - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details) - shares	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Stock options outstanding (in shares)	15,264,606	13,462,963	11,845,376	8,434,988
Stock options available for grant (in shares)	1,354,280
Employee stock purchase plan (in shares)	195,818
Warrants outstanding (in shares)	640,164
Shares of common stock underlying Convertible Notes outstanding (see Note 8) (in shares)	8,472,820
Total shares reserved for future issuance (in shares)	25,927,688

Note 9 - Stockholders' Equity - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of shares outstanding (in shares)	13,462,963	11,845,376	8,434,988
Number of shares outstanding, weighted average exercise price (in dollars per share)	$ 15.03	$ 14.44	$ 13.64
Number of shares granted (in shares)	4,052,011	4,300,621	4,920,661
Number of shares granted, weighted average exercise price (in dollars per share)	$ 26.83	$ 16.17	$ 15.98
Number of shares exercised (in shares)	(1,529,509)	(1,350,605)	(798,363)
Number of shares exercised, weighted average exercise price (in dollars per share)	$ 11.97	$ 8.49	$ 8.37
Number of shares cancelled (in shares)	(720,859)	(1,332,429)	(711,910)
Number of shares cancelled, weighted average exercise price (in dollars per share)	$ 17.98	$ 20.06	$ 22.43
Number of shares outstanding (in shares)	15,264,606	13,462,963	11,845,376
Number of shares outstanding, weighted average exercise price (in dollars per share)	$ 18.33	$ 15.03	$ 14.44

Note 9 - Stockholders' Equity - Options Exercisable, Vested or Expected to Vest (Details) - $ / shares	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Options exercisable at end of year (in shares)	6,523,093	5,446,586	4,356,665
Options exercisable at end of year, weighted average exercise price (in dollars per share)	$ 14.83	$ 13.25	$ 11.66
Options vested or expected to vest (in shares)	14,449,017	12,854,571	11,234,529
Options vested or expected to vest, weighted average exercise price (in dollars per share)	$ 18.11	$ 14.98	$ 14.32

Note 9 - Stockholders' Equity - Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2018 $ / shares shares
Options Outstanding (in shares) \| shares	15,264,606
Exercise Price Range 1 [Member]
Options Outstanding (in shares) \| shares	2,635,453
Range of Exercise Prices, Lower Limit (in dollars per share)	$ 5.20
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 9.05
Weighted- Average Remaining Contractual Life (Year)	3 years 10 days
Weighted- Average Exercise Price (in dollars per share)	$ 7.99
Options Exercisable (in shares) \| shares	2,260,453
Weighted- Average Exercise Price of Options Exercisable (in dollars per share)	$ 8.12
Exercise Price Range 2 [Member]
Options Outstanding (in shares) \| shares	2,531,622
Range of Exercise Prices, Lower Limit (in dollars per share)	$ 9.33
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 14.20
Weighted- Average Remaining Contractual Life (Year)	6 years 105 days
Weighted- Average Exercise Price (in dollars per share)	$ 12.89
Options Exercisable (in shares) \| shares	1,406,228
Weighted- Average Exercise Price of Options Exercisable (in dollars per share)	$ 12.66
Exercise Price Range 3 [Member]
Options Outstanding (in shares) \| shares	4,195,066
Range of Exercise Prices, Lower Limit (in dollars per share)	$ 14.25
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 17
Weighted- Average Remaining Contractual Life (Year)	7 years 284 days
Weighted- Average Exercise Price (in dollars per share)	$ 16.60
Options Exercisable (in shares) \| shares	1,512,260
Weighted- Average Exercise Price of Options Exercisable (in dollars per share)	$ 16.54
Exercise Price Range 4 [Member]
Options Outstanding (in shares) \| shares	845,157
Range of Exercise Prices, Lower Limit (in dollars per share)	$ 17.05
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 23.90
Weighted- Average Remaining Contractual Life (Year)	7 years 204 days
Weighted- Average Exercise Price (in dollars per share)	$ 20.52
Options Exercisable (in shares) \| shares	478,721
Weighted- Average Exercise Price of Options Exercisable (in dollars per share)	$ 20.64
Exercise Price Range 5 [Member]
Options Outstanding (in shares) \| shares	2,860,911
Range of Exercise Prices, Lower Limit (in dollars per share)	$ 24.97
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 24.97
Weighted- Average Remaining Contractual Life (Year)	8 years 343 days
Weighted- Average Exercise Price (in dollars per share)	$ 24.97
Options Exercisable (in shares) \| shares
Weighted- Average Exercise Price of Options Exercisable (in dollars per share)
Exercise Price Range 6 [Member]
Options Outstanding (in shares) \| shares	2,196,397
Range of Exercise Prices, Lower Limit (in dollars per share)	$ 25.06
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 39.25
Weighted- Average Remaining Contractual Life (Year)	7 years 153 days
Weighted- Average Exercise Price (in dollars per share)	$ 30.85
Options Exercisable (in shares) \| shares	865,431
Weighted- Average Exercise Price of Options Exercisable (in dollars per share)	$ 29.71
Exercise Price Range 7 [Member]
Options Outstanding (in shares) \| shares	15,264,606
Range of Exercise Prices, Lower Limit (in dollars per share)	$ 5.20
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 39.25
Weighted- Average Remaining Contractual Life (Year)	6 years 317 days
Weighted- Average Exercise Price (in dollars per share)	$ 18.33
Options Exercisable (in shares) \| shares	6,523,093
Weighted- Average Exercise Price of Options Exercisable (in dollars per share)	$ 14.83

Note 9 - Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Stock-based compensation expense	$ 33,367	$ 30,538	$ 25,956
Research and Development Expense [Member]
Stock-based compensation expense	13,689	11,312	11,316
General and Administrative Expense [Member]
Stock-based compensation expense	9,630	9,469	7,402
Selling and Marketing Expense [Member]
Stock-based compensation expense	$ 10,048	$ 9,757	$ 7,238

Note 9 - Stockholders' Equity - Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Stock Option [Member]
Risk-free interest rate	2.80%	2.10%	1.70%
Dividend yield
Volatility	70.40%	74.00%	89.10%
Expected life (Year)	6 years	6 years	6 years
Employee Stock Purchase Plan [Member]
Risk-free interest rate	2.40%	1.20%	0.40%
Dividend yield
Volatility	59.70%	50.00%	68.30%
Expected life (Year)	180 days	180 days	180 days

Note 10 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Expense (Benefit), Total	$ 0	$ 0	$ 0
Deferred Tax Assets, Tax Credit Carryforwards, Research	$ 35,670	$ 25,919
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	35.00%
Adjustment of Deferred Tax (Asset) Liability, Revaluation Based On New Tax Rate		$ 74,300
Unrecognized Tax Benefits, Ending Balance	$ 2,385	120	$ 120	$ 120
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0	0
Deferred Tax Assets Revaluated [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		$ (74,300)
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	715,300
Expiring Operating Loss Carryforwards	549,700
Indefinite Operating Loss Carryforwards	165,600
Deferred Tax Assets, Tax Credit Carryforwards, Research	27,200
State and Local Jurisdiction [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Research	13,300
State and Local Jurisdiction [Member] \| California Franchise Tax Board [Member]
Operating Loss Carryforwards, Total	122,300
State and Local Jurisdiction [Member] \| Other State Jurisdiction [Member]
Operating Loss Carryforwards, Total	$ 824,900

Note 10 - Income Taxes - Provisions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Tax at statutory federal rate	$ (37,557)	$ (67,145)	$ (58,868)
State tax, net of federal benefit	(6,527)	(6,203)	2,013
Research and development credits	(4,775)	(5,962)	(4,206)
Stock-based compensation expense	(2,059)	3,151	2,694
Non-deductible compensation	901		1,864
Change in valuation allowance	50,834	3,241	55,173
Impact of the 2017 Tax Act		74,361
Other	(817)	(1,443)	1,330
Provision for income taxes	$ 0	$ 0	$ 0

Note 10 - Income Taxes - Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforward	$ 172,113	$ 134,659
Research and development credits	35,670	25,919
Stock-based compensation	11,905	8,633
Other	3,171	2,920
Total gross deferred tax assets	222,859	172,131
Valuation allowance	(222,859)	(172,131)
Net deferred tax assets

Note 10 - Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Balance at beginning of year	$ 120	$ 120	$ 120
Additions for tax positions of prior years
Additions based on tax positions related to current year	2,265
Balance at end of year	$ 2,385	$ 120	$ 120

Note 11 - Other Income (Expense), Net (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Other Nonoperating Income (Expense), Total	$ 1,804	$ (38)	$ (9)
Disgorgement of Short-Swing Profits from the Sale of Common Stock [Member]
Other Nonoperating Income (Expense), Total	$ 1,900

Note 12 - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50.00%	50.00%	50.00%
Defined Contribution Plan, Maximum Annual Contributions by Employer per Employee, Amount	$ 8,250	$ 8,100	$ 7,950
Defined Contribution Plan, Cost	$ 700,000	$ 600,000	$ 600,000
Maximum [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	3.00%	3.00%	3.00%

Note 13 - Summary of Quarterly Consolidated Financial Data (Unaudited) - Summary Quarterly Results of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Net product sales	$ 28,844	$ 19,786	$ 17,277	$ 11,567	$ 10,053	$ 8,572	$ 8,510	$ 3,632	$ 77,474	$ 30,767	$ 1,279
Cost of product sales	(11,572)	(7,576)	(5,231)	(3,133)	(1,338)	(1,051)	(1,013)	(1,186)	(27,512)	(4,588)	(35)
Gross Profit	17,272	12,210	12,046	8,434	8,715	7,521	7,497	2,446
Operating expenses:
Research and development	39,891	30,421	30,159	39,561	47,757	28,844	28,597	33,384	140,032	138,582	103,125
General and administrative	8,738	7,288	6,209	7,028	6,165	6,462	6,185	6,742	29,263	25,554	21,366
Sales and marketing	19,957	16,281	14,531	13,835	16,683	13,529	14,770	11,619	64,604	56,601	47,668
Loss from operations	(51,314)	(41,780)	(38,853)	(51,990)	(61,890)	(41,314)	(42,055)	(49,299)
Other income (expense), net	1,755	3,434	183	(275)	(600)	(552)	(744)	(1,030)	5,097	(2,926)	(2,228)
Net loss	$ (49,559)	$ (38,346)	$ (38,670)	$ (52,265)	$ (62,490)	$ (41,866)	$ (42,799)	$ (50,329)	$ (178,840)	$ (197,484)	$ (173,143)
Basic and diluted net loss per share (in dollars per share)	$ (0.63)	$ (0.49)	$ (0.54)	$ (0.81)	$ (1.09)	$ (0.77)	$ (0.80)	$ (1)	$ (2.44)	$ (3.65)	$ (4.56)